<?xml version="1.0" encoding="UTF-8" ?>
<pdf>
    <fonts>
        <font id="simsun"     embedded="true" name="simsun"     ttf_path="/Users/zhaolisong/Desktop/projects/cooltoo/parse_pdf/templates/template_medicine_selected/simsun.ttc,1"/>
        <font id="fzlthjw"    embedded="true" name="fzlthjw"    ttf_path="/Users/zhaolisong/Desktop/projects/cooltoo/parse_pdf/templates/template_medicine_selected/fzlthjw.ttf"/>
        <font id="fzltchjw"   embedded="true" name="fzltchjw"   ttf_path="/Users/zhaolisong/Desktop/projects/cooltoo/parse_pdf/templates/template_medicine_selected/fzltchjw.ttf"/>
        <font id="fzltxh_gbk" embedded="true" name="fzltxh_gbk" ttf_path="/Users/zhaolisong/Desktop/projects/cooltoo/parse_pdf/templates/template_medicine_selected/fzltxh_gbk.ttf"/>
    </fonts>






    <data>
        <parameter id="diseaseName" value="（肺癌）"/>
        <parameter id="name"   value="王辉"/>
        <parameter id="gender" value="女"/>
        <parameter id="age" value="55"/>
        <parameter id="diagnoses" value="原发性肝细胞癌，中分化"/>
        <parameter id="sampleNumb" value="1234567890123456"/>
        <parameter id="sampleType" value="肿瘤组织"/>
        <parameter id="collectDate" value="2017 / 05 / 01"/>
        <parameter id="receiveDate" value="2017 / 05 / 10"/>
        <parameter id="admissionNumb" value="20170510—12342314"/>
        <parameter id="familyHistory" value="">
            <![CDATA[其肿瘤家族史未知。<br/>]]>
        </parameter>
        <parameter id="checkContent" value="">
            <![CDATA[· 检测内容:肿瘤靶向化疗用药标准检测<br/>
· 检测方法:高通量测序<br/>
· 主要设备:<br/>
· 数据分析软件及库:序列比对软件 BWA, 检测突变软件 Freebayes; 临床数据库: PharmGKB, HGMD, ClinVar, COSMIC, SNPedia, 1000genomes, dbSNP<br/>
]]>
        </parameter>
        <parameter id="appendixReferences" value="">
<![CDATA[1. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-1634.
<br/><br/>2. Ascierto P A, Minor D, Ribas A, et al. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma[J]. Journal of Clinical Oncology, 2013, 31(26): 3205-3211.
<br/><br/>3. Bachelot T, Bourgier C, Cropet C, et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor–positive, human epidermal growth factor receptor 2–negative metastatic breast cancer with prior exposure to aromatase inhibitors: A GINECO study[J]. Journal of Clinical Oncology, 2012, 30(22): 2718-2724.
<br/><br/>4. Bang Y J, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial[J]. The Lancet, 2010, 376(9742): 687-697.
<br/><br/>5. Barlesi F, Scherpereel A, Rittmeyer A, et al. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non–small-cell lung cancer: AVAPERL (MO22089)[J]. Journal of Clinical Oncology, 2013, 31(24): 3004-3011.
<br/><br/>6. Baselga J, Bradbury I, Eidtmann H, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial[J]. The Lancet, 2012, 379(9816): 633-640.
<br/><br/>7. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor–positive advanced breast cancer[J]. New England Journal of Medicine, 2012, 366(6): 520-529.
<br/><br/>8. Baselga J, Cortés J, Kim S B, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer[J]. New England Journal of Medicine, 2012, 366(2): 109-119.
<br/><br/>9. Baselga J, Semiglazov V, van Dam P, et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor–positive breast cancer[J]. Journal of Clinical Oncology, 2009, 27(16): 2630-2637.
<br/><br/>10. Bennouna J, Sastre J, Arnold D, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial[J]. The lancet oncology, 2013, 14(1): 29-37.
<br/><br/>11. Berns K, Horlings H M, Hennessy B T, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer[J]. Cancer cell, 2007, 12(4): 395-402.
<br/><br/>12. Blanke C D, Demetri G D, Von Mehren M, et al. Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT[J]. Journal of Clinical Oncology, 2008, 26(4): 620-625.
<br/><br/>13. Camidge D R, Bang Y J, Kwak E L, et al. Activity and safety of crizotinib in patients with ALK-positive non- small-cell lung cancer: updated results from a phase 1 study[J]. The lancet oncology, 2012, 13(10): 1011-1019.
<br/><br/>14. Chapman P B, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation[J]. New England Journal of Medicine, 2011, 364(26): 2507-2516.
<br/><br/>15. Cizkova M, Dujaric M E, Lehmann-Che J, et al. Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab[J]. British journal of cancer, 2013, 108(9): 1807-1809.
<br/><br/>16. Contreras A, Herrera S, Wang T, et al. Abstract PD1-2: PIK3CA mutations and/or low PTEN predict resistance to combined anti-HER2 therapy with lapatinib and trastuzumab and without chemotherapy in TBCRC006, a neoadjuvant trial of HER2-positive breast cancer patients[J]. Cancer Research, 2013, 73(24 Supplement): PD1-2-PD1-2.
<br/><br/>17. Corless C L, Schroeder A, Griffith D, et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib[J]. Journal of clinical oncology, 2005, 23(23): 5357-5364.
<br/><br/>18. Cui C, Mao L, Chi Z, et al. A phase II, randomized, double-blind, placebo-controlled multicenter trial of Endostar in patients with metastatic melanoma[J]. Molecular Therapy, 2013, 21(7): 1456-1463.
<br/><br/>19. De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis[J]. The lancet oncology, 2010, 11(8): 753-762.
<br/><br/>20. Debiec-Rychter M, Dumez H, Judson I, et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group[J]. European Journal of Cancer, 2004, 40(5): 689- 695.
<br/><br/>21. Debiec-Rychter M, Dumez H, Judson I, et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group[J]. European Journal of Cancer, 2004, 40(5): 689- 695.
<br/><br/>22. Debiec-Rychter M, Sciot R, Le Cesne A, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours[J]. European journal of cancer, 2006, 42(8): 1093-1103.
<br/><br/>23. Di Fiore F, Blanchard F, Charbonnier F, et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy[J]. British journal of cancer, 2007, 96(8): 1166-1169.
<br/><br/>24. Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer[J]. Journal of Clinical Oncology, 2008, 26(35): 5705-5712.
<br/><br/>25. Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factorreceptor and in KRAS are predictive and prognostic indicators in patients with non-smallcell lung cancer treated with chemotherapy alone and in combination with erlotinib. J ClinOncol 2005;23:5900-5909.
<br/><br/>26. Esteva F J, Guo H, Zhang S, et al. PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer[J]. The American journal of pathology, 2010, 177(4): 1647-1656.
<br/><br/>27. Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non–small cell lung cancer[J]. Cancer discovery, 2014, 4(6): 662-673.
<br/><br/>28. Fujita T, Doihara H, Kawasaki K, et al. PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer[J]. British journal of cancer, 2006, 94(2): 247-252.
<br/><br/>29. Gajiwala K S, Wu J C, Christensen J, et al. KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients[J]. Proceedings of the National Academy of Sciences, 2009, 106(5): 1542-1547.
<br/><br/>30. Gautschi O, Pauli C, Strobel K, et al. A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib[J]. Journal of Thoracic Oncology, 2012, 7(10): e23-e24.
<br/><br/>31. Geyer C E, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer[J]. New England Journal of Medicine, 2006, 355(26): 2733-2743.
<br/><br/>32. Gianni L, Pienkowski T, Im Y H, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial[J]. The lancet oncology, 2012, 13(1): 25-32.
<br/><br/>33. Guo J, Si L, Kong Y, et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification[J]. Journal of Clinical Oncology, 2011, 29(21): 2904-2909.
<br/><br/>34. Hauschild A, Grob J J, Demidov L V, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial[J]. The Lancet, 2012, 380(9839): 358-365.
<br/><br/>35. Hodi F S, Corless C L, Giobbie-Hurder A, et al. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin[J]. Journal of Clinical Oncology, 2013, 31(26): 3182-3190.
<br/><br/>36. Hyman D M, Puzanov I, Subbiah V, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations[J]. New England Journal of Medicine, 2015, 373(8): 726-736.
<br/><br/>37. Jhawer M, Goel S, Wilson A J, et al. PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab[J]. Cancer research, 2008, 68(6): 1953- 1961.
<br/><br/>38. Johnson D B, Flaherty K T, Weber J S, et al. Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor[J]. Journal of Clinical Oncology, 2014, 32(33): 3697-3704.
<br/><br/>39. Kim K B, Kefford R, Pavlick A C, et al. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor[J]. Journal of Clinical Oncology, 2013, 31(4): 482-489.
<br/><br/>40. Kindler H L, Friberg G, Singh D A, et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer[J]. Journal of Clinical Oncology, 2005, 23(31): 8033-8040.
<br/><br/>41. Lasota J, Miettinen M. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours[J]. Histopathology, 2008, 53(3): 245-266.
<br/><br/>42. Laurent-Puig P, Cayre A, Manceau G, et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer[J]. Journal of Clinical Oncology, 2009, 27(35): 5924-5930.
<br/><br/>43. Lièvre A, Bachet J B, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab[J]. Journal of Clinical Oncology, 2008, 26(3): 374-379.
<br/><br/>44. Lievre A, Bachet J B, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer[J]. Cancer research, 2006, 66(8): 3992-3995.
<br/><br/>45. Lin N U, Diéras V, Paul D, et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer[J]. Clinical Cancer Research, 2009, 15(4): 1452-1459.
<br/><br/>46. Linardou H, Dahabreh I J, Kanaloupiti D, et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer[J]. The lancet oncology, 2008, 9(10): 962-972.
<br/><br/>47. Long G V, Stroyakovskiy D, Gogas H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial[J]. The Lancet, 2015, 386(9992): 444-451.
<br/><br/>48. Long G V, Trefzer U, Davies M A, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial[J]. The lancet oncology, 2012, 13(11): 1087-1095.
<br/><br/>49. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non–small-cell lung cancer with mutated EGFR[J]. New England Journal of Medicine, 2010, 362(25): 2380-2388.
<br/><br/>50. Masi G, Loupakis F, Salvatore L, et al. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial[J]. The lancet oncology, 2010, 11(9): 845-852.
<br/><br/>51. Mazières J, Zalcman G, Crinò L, et al. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort[J]. Journal of Clinical Oncology, 2015, 33(9): 992-999.
<br/><br/>52. McArthur G A, Chapman P B, Robert C, et al. Safety and efficacy of vemurafenib in BRAF V600E and BRAF V600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study[J]. The lancet oncology, 2014, 15(3): 323-332.
<br/><br/>53. Miles D W, Chan A, Dirix L Y, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2–negative metastatic breast cancer[J]. Journal of Clinical Oncology, 2010, 28(20): 3239-3247.
<br/><br/>54. Nagata Y, Lan K H, Zhou X, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients[J]. Cancer cell, 2004, 6(2): 117-127.
<br/><br/>55. Nishida T, Takahashi T, Nishitani A, et al. Sunitinib-resistant gastrointestinal stromal tumors harbor cis- mutations in the activation loop of the KIT gene[J]. International journal of clinical oncology, 2009, 14(2): 143- 149.
<br/><br/>56. Ohtsu A, Shah M A, Van Cutsem E, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study[J]. Journal of Clinical Oncology, 2011: JCO. 2011.36. 2236.
<br/><br/>57. Ou S H I, Bang Y J, Camidge D R, et al. Efficacy and safety of crizotinib in patients with advanced ROS1- rearranged non-small cell lung cancer (NSCLC)[C]//ASCO Annual Meeting Proceedings. 2013, 31(15_suppl): 8032.
<br/><br/>58. Ou S H I, Kwak E L, Siwak-Tapp C, et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification[J]. Journal of thoracic oncology, 2011, 6(5): 942-946.
<br/><br/>59. Paez J G, Janne P A, Lee J C, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy[J]. Science, 2004, 304(5676): 1497-1500.
<br/><br/>60. Paik PK, Varghese AM, Sima CS, et al. Response to erlotinib in patients with EGFR mutant advanced non- small cell lung cancers with a squamous or squamous-like component. Mol Cancer Ther 2012;11:2535-2540.
<br/><br/>61. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:e73.
<br/><br/>62. Pao W, Wang T Y, Riely G J, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib[J]. PLoS Med, 2005, 2(1): e17.
<br/><br/>63. Peeters M, Douillard J Y, Van Cutsem E, et al. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab[J]. Journal of Clinical Oncology, 2013, 31(6): 759-765.
<br/><br/>64. Peeters M, Oliner K S, Price T J, et al. Analysis of KRAS/NRAS mutations in a phase III study of panitumumab with FOLFIRI compared with FOLFIRI alone as second-line treatment for metastatic colorectal cancer[J]. Clinical Cancer Research, 2015, 21(24): 5469-5479.
<br/><br/>65. Pietrantonio F, Petrelli F, Coinu A, et al. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis[J]. European Journal of Cancer, 2015, 51(5): 587-594.
<br/><br/>66. Planchard D, Groen HJM, Min Kim T, et al. Interim results of a phase II study of the BRAF inhibitor dabrafenib in combination with the MEK inhibitor trametinib in patients with BRAF V600E mutated metastatic non-small cell lung cancer. J Clin Oncol 2015;33: Abstract 8006.
<br/><br/>67. Planchard D, Mazieres J, Riely GJ, et al. Interim results of phase II study BRF113928 of dabrafenib in BRAF V600E mutation-positive non-small cell lung cancer (NSCLC) patients [abstract]. J Clin Oncol 2013;31(Suppl 15): Abstract 8009.
<br/><br/>68. Razis E, Bobos M, Kotoula V, et al. Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer[J]. Breast cancer research and treatment, 2011, 128(2): 447-456.
<br/><br/>69. Robert N J, Diéras V, Glaspy J, et al. RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2–negative, locally recurrent or metastatic breast cancer[J]. Journal of Clinical Oncology, 2011, 29(10): 1252-1260.
<br/><br/>70. Robinson S D, O'Shaughnessy J A, Cowey C L, et al. BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib[J]. Lung Cancer, 2014, 85(2): 326-330.
<br/><br/>71. Romond E H, Perez E A, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2- positive breast cancer[J]. New England Journal of Medicine, 2005, 353(16): 1673-1684.
<br/><br/>72. Sandler A, Gray R, Perry M C, et al. Paclitaxel–carboplatin alone or with bevacizumab for non–small-cell lung cancer[J]. New England Journal of Medicine, 2006, 355(24): 2542-2550.
<br/><br/>73. Sartore-Bianchi A, Martini M, Molinari F, et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies[J]. Cancer research, 2009, 69(5): 1851-1857.
<br/><br/>74. Schneider B P, Wang M, Radovich M, et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100[J]. Journal of Clinical Oncology, 2008, 26(28): 4672-4678.
<br/><br/>75. Sequist L V, Martins R G, Spigel D, et al. First-line gefitinib in patients with advanced non–small-cell lung cancer harboring somatic EGFR mutations[J]. Journal of Clinical Oncology, 2008, 26(15): 2442-2449.
<br/><br/>76. Sequist L V, Yang J C H, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations[J]. Journal of Clinical Oncology, 2013, 31(27): 3327-3334.
<br/><br/>77. Seymour M T, Brown S R, Middleton G, et al. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial[J]. The lancet oncology, 2013, 14(8): 749-759.
<br/><br/>78. Shah M A, Ramanathan R K, Ilson D H, et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma[J]. Journal of Clinical Oncology, 2006, 24(33): 5201-5206.
<br/><br/>79. Shaw A T, Kim D W, Mehra R, et al. Ceritinib in ALK-rearranged non–small-cell lung cancer[J]. New England Journal of Medicine, 2014, 370(13): 1189-1197.
<br/><br/>80. Shaw A T, Kim D W, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer[J]. New England Journal of Medicine, 2013, 368(25): 2385-2394.
<br/><br/>81. Shaw A T, Ou S H I, Bang Y J, et al. Crizotinib in ROS1-rearranged non–small-cell lung cancer[J]. New England Journal of Medicine, 2014, 371(21): 1963-1971.
<br/><br/>82. Shaw A T, Yeap B Y, Solomon B J, et al. Effect of crizotinib on overall survival in patients with advanced non- small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis[J]. The lancet oncology, 2011, 12(11): 1004-1012.
<br/><br/>83. Shi Y, Zhang L, Liu X, et al. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial[J]. The lancet oncology, 2013, 14(10): 953-961.
<br/><br/>84. Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer[J]. New England Journal of Medicine, 2011, 365(14): 1273-1283.
<br/><br/>85. Sosman J A, Kim K B, Schuchter L, et al. Survival in BRAF V600–mutant advanced melanoma treated with vemurafenib[J]. New England Journal of Medicine, 2012, 366(8): 707-714.
<br/><br/>86. Swain S M, Kim S B, Cortés J, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo- controlled, phase 3 study[J]. The lancet oncology, 2013, 14(6): 461-471.
<br/><br/>87. Tebbutt N C, Wilson K, Gebski V J, et al. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study[J]. Journal of Clinical Oncology, 2010, 28(19): 3191-3198.
<br/><br/>88. Van Cutsem E, de Haas S, Kang Y K, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial[J]. Journal of Clinical Oncology, 2012: JCO. 2011.39. 9824.
<br/><br/>89. Van Cutsem E, Vervenne W L, Bennouna J, et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer[J]. Journal of Clinical Oncology, 2009, 27(13): 2231-2237.
<br/><br/>90. Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer[J]. New England Journal of Medicine, 2012, 367(19): 1783-1791.
<br/><br/>91. Wu Y L, Zhou C, Hu C P, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial[J]. The lancet oncology, 2014, 15(2): 213-222.
<br/><br/>92. Xiao L, Yang S C, Hao J, et al. Endostar attenuates melanoma tumor growth via its interruption of b-FGF mediated angiogenesis[J]. Cancer letters, 2015, 359(1): 148-154.
<br/><br/>93. Yang J C H, Hirsh V, Schuler M, et al. Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations[J]. Journal of Clinical Oncology, 2013: JCO. 2012.46. 1764.
<br/><br/>94. Zhu C Q, da Cunha Santos G, Ding K, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR. 21[J]. Journal of Clinical Oncology, 2008, 26(26): 4268-4275.
]]>
</parameter>
        <tree_node id="catalog" value="目录" english="" page="" catalog="0 0">
            <tree_node value="一" english="" page="" catalog="1 0">
                <tree_node english="" page="001" value="样本提供者信息" catalog="1 1">
                </tree_node>
            </tree_node>
            <tree_node value="二" english="" page="" catalog="2 0">
                <tree_node english="" page="xxx" value="个人病史及肿瘤家族史调查" catalog="2 1"/>
            </tree_node>
            <tree_node value="三" english="" page="" catalog="3 0">
                <tree_node english="" page="xxx" value="项目内容" catalog="3 1"/>
            </tree_node>
            <tree_node value="四" english="" page="" catalog="4 0">
                <tree_node english="" page="xxx" value="用药提示" catalog="4 1"/>
                <tree_node english="" page="xxx" value="分子靶向用药提示" catalog="4 2"/>
                <tree_node english="" page="xxx" value="靶向药物简述" catalog="4 3"/>
            </tree_node>
            <tree_node value="五" english="" page="" catalog="5 0">
                <tree_node english="" page="xxx" value="本次检测具体位点结果"   catalog="5 1 0"/>
                <tree_node english="" page="xxx" value="本次检测的分子靶向基因" catalog="5 2 0"/>
            </tree_node>
            <tree_node value="六" english="" page="" catalog="6 0">
                <tree_node english="" page="xxx" value="本次检测的基因列表" catalog="6 1"/>
            </tree_node>
            <tree_node value="附录" english="Appendix" page="" catalog="10000 0 0">
                <tree_node english="" page="xxx" value="靶向用药表格说明示例" catalog="10000 1"/>
                <tree_node english="" page="xxx" value="常见癌种中的靶向药物简介，FDA 获批适应症及 NCCN 指导意见" catalog="10000 2"/>
                <tree_node english="" page="xxx" value="参考文献"      catalog="10000 3"/>
            </tree_node>
        </tree_node>

        <table id="detailBaXiangMedicineList">
            <headers>
                <header column="0" value="药品"/>
                <header column="1" value="英文名称"/>
                <header column="2" value="靶点"/>
                <header column="3" value="获批资格"/>
            </headers>
            <rows>
                <cell row="0"  column="0" value="厄洛替尼"/>
                <cell row="1"  column="0" value="吉非替尼"/>
                <cell row="2"  column="0" value="克唑替尼"/>
                <cell row="3"  column="0" value="阿法替尼"/>
                <cell row="4"  column="0" value="贝伐珠单抗"/>
                <cell row="5"  column="0" value="阿雷替尼"/>
                <cell row="6"  column="0" value="色瑞替尼"/>
                <cell row="7"  column="0" value="纳武单抗"/>
                <cell row="8"  column="0" value="Tagrisso"/>
                <cell row="9"  column="0" value="雷莫芦单抗"/>
                <cell row="10" column="0" value="维罗非尼"/>

                <cell row="0"  column="1" value="Erlotinib"/>
                <cell row="1"  column="1" value="Gefitinib"/>
                <cell row="2"  column="1" value="Crizotinib"/>
                <cell row="3"  column="1" value="Afatinib"/>
                <cell row="4"  column="1" value="Bevacizumab"/>
                <cell row="5"  column="1" value="Alectinib"/>
                <cell row="6"  column="1" value="Ceritinib"/>
                <cell row="7"  column="1" value="Nivolumab"/>
                <cell row="8"  column="1" value="Osimertinib"/>
                <cell row="9"  column="1" value="Ramucirumab"/>
                <cell row="10" column="1" value="Vemurafenib"/>

                <cell row="0"  column="2" value="EGFR"/>
                <cell row="1"  column="2" value="EGFR"/>
                <cell row="2"  column="2" value="ALK / ROS1 / MET"/>
                <cell row="3"  column="2" value="EGFR / HER2 / ERBB4"/>
                <cell row="4"  column="2" value="VEGF / KDR"/>
                <cell row="5"  column="2" value="ALK"/>
                <cell row="6"  column="2" value="ALK / IGF1R"/>
                <cell row="7"  column="2" value="PD-1"/>
                <cell row="8"  column="2" value="EGFR"/>
                <cell row="9"  column="2" value="VEGFR-2"/>
                <cell row="10" column="2" value="BRAF"/>

                <cell row="0"  column="3" value="EGFR"/>
                <cell row="1"  column="3" value="EGFR"/>
                <cell row="2"  column="3" value="ALK / ROS1 / MET"/>
                <cell row="3"  column="3" value="EGFR / HER2 / ERBB4"/>
                <cell row="4"  column="3" value="VEGF / KDR"/>
                <cell row="5"  column="3" value="ALK"/>
                <cell row="6"  column="3" value="ALK / IGF1R"/>
                <cell row="7"  column="3" value="PD-1"/>
                <cell row="8"  column="3" value="EGFR"/>
                <cell row="9"  column="3" value="VEGFR-2"/>
                <cell row="10" column="3" value="BRAF"/>
            </rows>
        </table>



        <repeat id="allDiseaseMedicineInfo">
            <group id="0" order="0">
                <parameter id="everyDiseaseName" value="1、非小细胞肺癌"/>
                <parameter id="adaptionDiseaseMedicineInfo" value="">
<![CDATA[
<style font='fzltchjw' font_color='#000000' font_size='13'>获批适应症：</style><br/>
<style font_color='#607b3f' font_size='10' bold='true' char_spacing='1.1'>Erlotinib</style><br/>
可用于治疗既往接受过至少一个化疗方案失败后的局部晚期或转移的非小细胞肺癌。NCCN2016 年版临床指南明确指出，肿瘤 EGFR 突变的前提下，推荐厄洛替尼为非小细胞肺癌一线治疗药物。<br/>
<style font_color='#607b3f' font_size='10' bold='true' char_spacing='1.1'>Gefitinib</style><br/>
可用于非小细胞肺癌的二线治疗。NCCN2016 年版临床指南明确指出，肿瘤 EGFR 突变的前提下，推荐吉非替尼为非小细胞肺癌一线治疗药物。<br/>
<style font_color='#607b3f' font_size='10' bold='true' char_spacing='1.1'>Crizotinib</style><br/>
可用于治疗 ALK 阳性的局部进展或晚期非小细胞肺癌。NCCN2016 年版临床指南明确指出，肿瘤 ALK 重排的前提下，推荐克唑替尼为非小细胞肺癌一线治疗药物。<br/>
<style font_color='#607b3f' font_size='10' bold='true' char_spacing='1.1'>Afatinib</style><br/>
可用于 EGFR 突变阳性的非小细胞肺癌治疗。NCCN2016 年版临床指南明确指出，肿瘤 EGFR 突变的前提下，推荐阿 法替尼为非小细胞肺癌一线治疗药物。<br/>
<style font_color='#607b3f' font_size='10' bold='true' char_spacing='1.1'>Bevacizumab</style><br/>
可用于治疗转移性非小细胞肺癌。NCCN2016 年版临床指南明确指出，贝伐单抗结合卡铂和紫杉醇作为 (PS0-1) 非小细胞肺癌的一线治疗方案。<br/>
<style font_color='#607b3f' font_size='10' bold='true' char_spacing='1.1'>Alectinib</style><br/>
可用于治疗非小细胞肺癌进展或不能耐受克唑替尼。<br/>
<style font_color='#607b3f' font_size='10' bold='true' char_spacing='1.1'>Ceritinib</style><br/>
可用于治疗转移性 ALK- 阳性非小细胞肺癌，且对克唑替尼耐药者。<br/>
<style font_color='#607b3f' font_size='10' bold='true' char_spacing='1.1'>Vemurafenib</style><br/>
可用于治疗不可切除或转移性恶性黑色素瘤，转移性鳞状非小细胞肺癌。<br/><br/>


<style font='fzltchjw' font_color='#000000' font_size='13'>药物简介：</style><br/>
<style font_color='#607b3f' font_size='10' bold='true' char_spacing='1.1'>Erlotinib</style><br/>
是一类靶向 EGFR 的小分子酪氨酸激酶抑制剂，该类药物通过阻断表皮生长因子受体（EGFR）的激酶活性而抑制其磷酸化和下游信号传导，从而起到抗肿瘤作用，抑制肿瘤细胞的增生、分化同时也能增加化疗和放疗的抗肿瘤疗效。<br/>
<style font_color='#607b3f' font_size='10' bold='true' char_spacing='1.1'>Gefitinib</style><br/>
是一类靶向 EGFR 的小分子酪氨酸激酶抑制剂，该类药物通过阻断表皮生长因子受体（EGFR）的激酶活性而抑制其磷酸化和下游信号传导，从而起到抗肿瘤作用，抑制肿瘤细胞的增生、分化同时也能增加化疗和放疗的抗肿瘤疗效。<br/>
<style font_color='#607b3f' font_size='10' bold='true' char_spacing='1.1'>Crizotinib</style><br/>
是靶向 ALK／MET 的小分子酪氨酸双激酶抑制剂，该药物以 ATP 竞争的方式，结合并抑制 ALK 激酶 ALK 融合蛋白。此外，克唑替尼还抑制 MET 激酶，阻断细胞内信号转导，从而抑制癌细胞的增殖。<br/>
<style font_color='#607b3f' font_size='10' bold='true' char_spacing='1.1'>Afatinib</style><br/>
是靶向 EGFR／HER2 小分子酪氨酸激酶的不可逆抑制剂，作为第二代高效双重非可逆性的酪氨酸激酶抑制剂，可同时抑制 EGFR 和 HER2 两种受体，共价结合 EGFR、HER2 的激酶区域，不可逆的抑制酪氨酸激酶的自磷酸化，导致下游信号通路的下调，抑制肿瘤细胞的增殖和生长。<br/>
<style font_color='#607b3f' font_size='10' bold='true' char_spacing='1.1'>Bevacizumab</style><br/>
为重组人源化单克隆抗体。通过体内、体外检测系统证实 IgG1 抗体能与人血管内皮生长因子（VEGF）结合并阻断其生物 活性。而阿瓦斯汀包含了人源抗体的结构区和可结合 VEGF 的鼠源单抗的互补决定区。因此阿瓦斯汀能与 VEGF 结合从而使 VEGF 不能与它的受体 FLT-1 和 KDR 在内皮细胞表面结合，从而抑制内皮细胞增殖和新的肿瘤血管形成。<br/>
<style font_color='#607b3f' font_size='10' bold='true' char_spacing='1.1'>Alectinib</style><br/>
是一种 ALK 抑制剂。<br/>
<style font_color='#607b3f' font_size='10' bold='true' char_spacing='1.1'>Ceritinib</style><br/>
是一种 ALK 抑制剂。<br/>
<style font_color='#607b3f' font_size='10' bold='true' char_spacing='1.1'>Vemurafenib</style><br/>
是一种 BRAF 激酶抑制剂。<br/><br/>
]]>
                </parameter>
                <table id="everyDiseaseMedicine">
                    <headers>
                        <header column="0" value="药品"/>
                        <header column="1" value="英文名称"/>
                        <header column="2" value="靶点"/>
                        <header column="3" value="获批资格"/>
                    </headers>
                    <rows>
                        <cell row="0"  column="0" value="厄洛替尼"/>
                        <cell row="1"  column="0" value="吉非替尼"/>
                        <cell row="2"  column="0" value="克唑替尼"/>
                        <cell row="3"  column="0" value="阿法替尼"/>
                        <cell row="4"  column="0" value="贝伐珠单抗"/>
                        <cell row="5"  column="0" value="阿雷替尼"/>
                        <cell row="6"  column="0" value="色瑞替尼"/>
                        <cell row="7"  column="0" value="纳武单抗"/>
                        <cell row="8"  column="0" value="Tagrisso"/>
                        <cell row="9"  column="0" value="雷莫芦单抗"/>
                        <cell row="10" column="0" value="维罗非尼"/>

                        <cell row="0"  column="1" value="Erlotinib"/>
                        <cell row="1"  column="1" value="Gefitinib"/>
                        <cell row="2"  column="1" value="Crizotinib"/>
                        <cell row="3"  column="1" value="Afatinib"/>
                        <cell row="4"  column="1" value="Bevacizumab"/>
                        <cell row="5"  column="1" value="Alectinib"/>
                        <cell row="6"  column="1" value="Ceritinib"/>
                        <cell row="7"  column="1" value="Nivolumab"/>
                        <cell row="8"  column="1" value="Osimertinib"/>
                        <cell row="9"  column="1" value="Ramucirumab"/>
                        <cell row="10" column="1" value="Vemurafenib"/>

                        <cell row="0"  column="2" value="EGFR"/>
                        <cell row="1"  column="2" value="EGFR"/>
                        <cell row="2"  column="2" value="ALK / ROS1 / MET"/>
                        <cell row="3"  column="2" value="EGFR / HER2 / ERBB4"/>
                        <cell row="4"  column="2" value="VEGF / KDR"/>
                        <cell row="5"  column="2" value="ALK"/>
                        <cell row="6"  column="2" value="ALK / IGF1R"/>
                        <cell row="7"  column="2" value="PD-1"/>
                        <cell row="8"  column="2" value="EGFR"/>
                        <cell row="9"  column="2" value="VEGFR-2"/>
                        <cell row="10" column="2" value="BRAF"/>

                        <cell row="0"  column="3" value="EGFR"/>
                        <cell row="1"  column="3" value="EGFR"/>
                        <cell row="2"  column="3" value="ALK / ROS1 / MET"/>
                        <cell row="3"  column="3" value="EGFR / HER2 / ERBB4"/>
                        <cell row="4"  column="3" value="VEGF / KDR"/>
                        <cell row="5"  column="3" value="ALK"/>
                        <cell row="6"  column="3" value="ALK / IGF1R"/>
                        <cell row="7"  column="3" value="PD-1"/>
                        <cell row="8"  column="3" value="EGFR"/>
                        <cell row="9"  column="3" value="VEGFR-2"/>
                        <cell row="10" column="3" value="BRAF"/>
                    </rows>
                </table>
            </group>
            <group id="1" order="1">
                <parameter id="everyDiseaseName" value="2、肝癌"/>
                <parameter id="adaptionDiseaseMedicineInfo" value="">
                    <![CDATA[
<style font='fzltchjw' font_color='#000000' font_size='13'>获批适应症：</style><br/>
<style font_color='#607b3f' font_size='10' bold='true' char_spacing='1.1'>Sorafenib</style><br/>
可用于治疗肝细胞癌。NCCN2016 年版临床指南明确指出，建议索拉菲尼用于治疗局限或转移性肝癌。<br/><br/>


<style font='fzltchjw' font_color='#000000' font_size='13'>药物简介：</style><br/>
<style font_color='#607b3f' font_size='10' bold='true' char_spacing='1.1'>Vemurafenib</style><br/>
是一种针对丝氨酸／苏氨酸和酪氨酸激酶受体的多激酶抑制剂，抑制肿瘤细胞的生长和增殖，促进细胞凋亡。<br/><br/>
]]>
                </parameter>
                <table id="everyDiseaseMedicine">
                    <headers>
                        <header column="0" value="药品"/>
                        <header column="1" value="英文名称"/>
                        <header column="2" value="靶点"/>
                        <header column="3" value="获批资格"/>
                    </headers>
                    <rows>
                        <cell row="0"  column="0" value="索拉非尼"/>

                        <cell row="0"  column="1" value="Sorafenib"/>

                        <cell row="0"  column="2" value="BRAF／KIT／KDR／PDGFRA"/>

                        <cell row="0"  column="3" value="FDA／CFDA"/>
                    </rows>
                </table>
            </group>
            <group id="2" order="2">
                <parameter id="everyDiseaseName" value="3、Fei癌"/>
                <parameter id="adaptionDiseaseMedicineInfo" value="">
                    <![CDATA[
<style font='fzltchjw' font_color='#000000' font_size='13'>获批适应症：</style><br/>
<style font_color='#607b3f' font_size='10' bold='true' char_spacing='1.1'>Erlotinib</style><br/>
可用于治疗既往接受过至少一个化疗方案失败后的局部晚期或转移的非小细胞肺癌。NCCN2016 年版临床指南明确指出，肿瘤 EGFR 突变的前提下，推荐厄洛替尼为非小细胞肺癌一线治疗药物。<br/>
<style font_color='#607b3f' font_size='10' bold='true' char_spacing='1.1'>Gefitinib</style><br/>
<style font_color='#607b3f' font_size='10' bold='true' char_spacing='1.1'>Alectinib</style><br/>
可用于治疗非小细胞肺癌进展或不能耐受克唑替尼。<br/>
<style font_color='#607b3f' font_size='10' bold='true' char_spacing='1.1'>Ceritinib</style><br/>
可用于治疗转移性 ALK- 阳性非小细胞肺癌，且对克唑替尼耐药者。<br/>
<style font_color='#607b3f' font_size='10' bold='true' char_spacing='1.1'>Nivolumab</style><br/>
可用于治疗转移性鳞状非小细胞肺癌。<br/>
<style font_color='#607b3f' font_size='10' bold='true' char_spacing='1.1'>Osimertinib</style><br/>
可用于治疗 EGFR-T790M 突变阳性的非小细胞肺癌。<br/>
<style font_color='#607b3f' font_size='10' bold='true' char_spacing='1.1'>Ramucirumab</style><br/>
可用于治疗转移性非小细胞肺癌（经铂类联合多西他赛治疗期间或治疗后疾病仍然无进展的患者）。<br/>
<style font_color='#607b3f' font_size='10' bold='true' char_spacing='1.1'>Vemurafenib</style><br/>
可用于治疗不可切除或转移性恶性黑色素瘤，转移性鳞状非小细胞肺癌。<br/><br/>


<style font='fzltchjw' font_color='#000000' font_size='13'>药物简介：</style><br/>
<style font_color='#607b3f' font_size='10' bold='true' char_spacing='1.1'>Erlotinib</style><br/>
是一类靶向 EGFR 的小分子酪氨酸激酶抑制剂，该类药物通过阻断表皮生长因子受体（EGFR）的激酶活性而抑制其磷酸化和下游信号传导，从而起到抗肿瘤作用，抑制肿瘤细胞的增生、分化同时也能增加化疗和放疗的抗肿瘤疗效。<br/>
<style font_color='#607b3f' font_size='10' bold='true' char_spacing='1.1'>Alectinib</style><br/>
是一种 ALK 抑制剂。<br/>
<style font_color='#607b3f' font_size='10' bold='true' char_spacing='1.1'>Ceritinib</style><br/>
是一种 ALK 抑制剂。<br/>
<style font_color='#607b3f' font_size='10' bold='true' char_spacing='1.1'>Nivolumab</style><br/>
是一种人类的 IgG4 和抗 PD-1 单克隆抗体。<br/>
<style font_color='#607b3f' font_size='10' bold='true' char_spacing='1.1'>Osimertinib</style><br/>
是第三代表皮生长因子（EGFR）酪氨酸激酶抑制剂药物（TKI)。<br/>
<style font_color='#607b3f' font_size='10' bold='true' char_spacing='1.1'>Ramucirumab</style><br/>
是实体肿瘤的治疗开发的完全人单克隆抗体（IgG1)。<br/>
<style font_color='#607b3f' font_size='10' bold='true' char_spacing='1.1'>Vemurafenib</style><br/>
是一种 BRAF 激酶抑制剂。<br/><br/>
]]>
                </parameter>
                <table id="everyDiseaseMedicine">
                    <headers>
                        <header column="0" value="药品"/>
                        <header column="1" value="英文名称"/>
                        <header column="2" value="靶点"/>
                        <header column="3" value="获批资格"/>
                    </headers>
                    <rows>
                        <cell row="0"  column="0" value="厄洛替尼"/>
                        <cell row="1"  column="0" value="吉非替尼"/>
                        <cell row="2"  column="0" value="克唑替尼"/>
                        <cell row="3"  column="0" value="阿法替尼"/>
                        <cell row="4"  column="0" value="贝伐珠单抗"/>
                        <cell row="5"  column="0" value="阿雷替尼"/>

                        <cell row="0"  column="1" value="Erlotinib"/>
                        <cell row="1"  column="1" value="Gefitinib"/>
                        <cell row="2"  column="1" value="Crizotinib"/>
                        <cell row="3"  column="1" value="Afatinib"/>
                        <cell row="4"  column="1" value="Bevacizumab"/>
                        <cell row="5"  column="1" value="Alectinib"/>

                        <cell row="0"  column="2" value="EGFR"/>
                        <cell row="1"  column="2" value="EGFR"/>
                        <cell row="2"  column="2" value="ALK / ROS1 / MET"/>
                        <cell row="3"  column="2" value="EGFR / HER2 / ERBB4"/>
                        <cell row="4"  column="2" value="VEGF / KDR"/>
                        <cell row="5"  column="2" value="ALK"/>

                        <cell row="0"  column="3" value="EGFR"/>
                        <cell row="1"  column="3" value="EGFR"/>
                        <cell row="2"  column="3" value="ALK / ROS1 / MET"/>
                        <cell row="3"  column="3" value="EGFR / HER2 / ERBB4"/>
                        <cell row="4"  column="3" value="VEGF / KDR"/>
                        <cell row="5"  column="3" value="ALK"/>
                    </rows>
                </table>
            </group>
        </repeat>
        <table id="targetedDrugUsageInfo">
            <headers>
                <header column="0"  value="基因名称"/>
                <header column="1"  value="是否突变"/>
                <header column="2"  value="突变位点"/>
                <header column="3"  value="突变频率"/>
                <header column="4"  value="敏感药物"/>
                <header column="5"  value="证据级别"/>
                <header column="6"  value="不敏感药物"/>
                <header column="7"  value="证据级别"/>
                <header column="8"  value="敏感药物"/>
                <header column="9"  value="证据级别"/>
                <header column="10" value="不敏感药物"/>
                <header column="11" value="证据级别"/>
            </headers>
            <rows>
                <cell row="0"  column="0" value="KRAS"/>
                <cell row="1"  column="0" value="KIT"/>

                <cell row="0"  column="1" value="是"/>
                <cell row="1"  column="1" value="是"/>

                <cell row="0"  column="2" value="p.G12D"/>
                <cell row="1"  column="2" value="p.N512K"/>

                <cell row="0"  column="3" value="32.8%"/>
                <cell row="1"  column="3" value="44.65%"/>

                <cell row="0"  column="4" value="／"/>
                <cell row="1"  column="4" value="索拉菲尼"/>

                <cell row="0"  column="5" value="／"/>
                <cell row="1"  column="5" value="A"/>

                <cell row="0"  column="6" value="瑞格菲尼"/>
                <cell row="1"  column="6" value="／"/>

                <cell row="0"  column="7" value="A"/>
                <cell row="1"  column="7" value="／"/>

                <cell row="0"  column="8" value="曲美替尼"/>
                <cell row="1"  column="8" value="伊马替尼 舒尼替尼 帕唑帕尼"/>

                <cell row="0"  column="9" value="C"/>
                <cell row="1"  column="9" value="C"/>

                <cell row="0"  column="10" value="／"/>
                <cell row="1"  column="10" value="／"/>

                <cell row="0"  column="11" value="／"/>
                <cell row="1"  column="11" value="／"/>
            </rows>
        </table>









        <table id="zhiBingJiYinYuZhongLiuGuanXi">
            <headers>
                <header column="0" value="癌种"/>
                <header column="1" value="基因数目"/>
                <header column="2" value="基因"/>
            </headers>
            <rows>
                <cell row="0"  column="0" value="乳腺癌"/>
                <cell row="1"  column="0" value="卵巢癌"/>
                <cell row="2"  column="0" value="结直肠癌"/>
                <cell row="3"  column="0" value="胃癌"/>
                <cell row="4"  column="0" value="肾癌"/>
                <cell row="5"  column="0" value="前列腺癌"/>
                <cell row="6"  column="0" value="胰腺癌"/>
                <cell row="7"  column="0" value="子宫内膜癌"/>
                <cell row="8"  column="0" value="甲状腺癌"/>
                <cell row="9"  column="0" value="甲状旁腺癌"/>
                <cell row="10" column="0" value="肺癌"/>
                <cell row="11" column="0" value="肝癌"/>
                <cell row="12" column="0" value="食管癌"/>
                <cell row="13" column="0" value="膀胱癌"/>
                <cell row="14" column="0" value="胶质瘤"/>
                <cell row="15" column="0" value="淋巴瘤"/>

                <cell row="0"  column="1" value="21"/>
                <cell row="1"  column="1" value="23"/>
                <cell row="2"  column="1" value="18"/>
                <cell row="3"  column="1" value="9"/>
                <cell row="4"  column="1" value="18"/>
                <cell row="5"  column="1" value="10"/>
                <cell row="6"  column="1" value="15"/>
                <cell row="7"  column="1" value="23"/>
                <cell row="8"  column="1" value="2"/>
                <cell row="9"  column="1" value="2"/>
                <cell row="10" column="1" value="5"/>
                <cell row="11" column="1" value="4"/>
                <cell row="12" column="1" value="4"/>
                <cell row="13" column="1" value="4"/>
                <cell row="14" column="1" value="4"/>
                <cell row="15" column="1" value="4"/>

                <cell row="0"  column="2" value="BRCA1, BRCA2, CHEK2, PALB2, BRIP1, TP53, PTEN, STK11, CDH1, ATM, BARD1, MLH1,MRE11A, MSH2, MSH6, MUTYH, NBN, PMS1, PMS2, RAD50, RAD51C"/>
                <cell row="1"  column="2" value="ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, EPCAM, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, NF1, PALB2, PMS2, PTEN, RAD50, RAD51C, RAD51D, STK11, TP53"/>
                <cell row="2"  column="2" value="APC, BMPR1A, CDH1, CHEK2, EPCAM, MLH1, MSH2, MSH6, MUTYH, PMS2, MET, PTEN, SMAD4, STK11, TP53, AXIN2, MLH3, BUB1"/>
                <cell row="3"  column="2" value="CDH1, TP53, MET, MLH1, MSH2, MSH6, PMS2, EPCAM, APC"/>
                <cell row="4"  column="2" value="EPCAM, FH, FLCN, MET, MITF, MLH1, MSH2, MSH6, PMS2, PTEN, SDHA, SDHB, SDHC, SDHD, TP53, TSC1, TSC2, VHL"/>
                <cell row="5"  column="2" value="BRCA2, BRCA1, CHEK2, NBN, HOXB13, ELAC2, HSD17B3, HSD3B2,  RNASEL, SRD5A2"/>
                <cell row="6"  column="2" value="APC, ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS2, STK11, TP53, PRSS1, SPINK1"/>
                <cell row="7"  column="2" value="ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, EPCAM, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, NF1, PALB2, PMS2, PTEN, RAD50, RAD51C, RAD51D, STK11, TP53"/>
                <cell row="8"  column="2" value="RET,NTRK1"/>
                <cell row="9"  column="2" value="MEN1, CDC73"/>
                <cell row="10" column="2" value="EGFR, PIK3CA, KRAS, BRAF, TP53"/>
                <cell row="11" column="2" value="TP53, IQGAP1, IQGAP2, CTNNB1"/>
                <cell row="12" column="2" value="RHBDF2, ADH1B, ALDH2, CYP2E1"/>
                <cell row="13" column="2" value="KRAS, RB1, FGFR3, HRAS"/>
                <cell row="14" column="2" value="P53, IDH1, IDH2, PTEN"/>
                <cell row="15" column="2" value="KLHDC8B, ATM, MYC, PRF1"/>
            </rows>
        </table>



















        <parameter id="gaiShuZhiBingJiYinJianShu" value="">
            <![CDATA[检出致病突变<br/>根据 NCBI GeneReviews <style font="simsun">®</style>, 该杂合突变者的直结肠癌风险轻微增加。<br/>请向医生或遗传咨询师咨询。<br/>]]>
        </parameter>
        <parameter id="gaiShuZhiBingJiYinJianChu" value="">
            <![CDATA[基因名词：<style italic="true">MUTYH</style> <br/> 该基因突变的可致疾病：直结肠癌 家族性腺瘤性息肉病<br/> 基因名词：<style italic="true">FAT3</style> <br/>该基因突变的可致疾病：直结肠癌 遗传性非息肉病<br/>]]>
        </parameter>
        <parameter id="gaiShuJiBingGeShu" value="15"/>
        <parameter id="gaiShuFengXianYuFangJianYi" value="">
<![CDATA[
<style font_size="12">根据肿瘤致病基因和风险基因的检测结果，您有结直肠癌的致病基因检出阳性</style><br/>
<style font_size="12">风险基因评分均 &lt;1.5</style><br/>
<style font_size="12">您的主要肿瘤风险为：</style>
<style font="fzlthjw" font_size="12" font_color="#738c34" bold="true">结直肠癌。</style> <br/>
<style font_size="12">请参考如下建议：</style><br/>
(参见结直肠癌的健康管理措施)<br/><br/>
<style font="fzltchjw" font_size="14" font_color="#607b3f">注意饮食</style><br/>
少吃脂肪，多吃富含膳食纤维的饮食。（剑桥大学的研究表明，高纤维饮食能有效减低患上致命癌症的危险几率达 40%，特别是结肠癌及直肠癌。）<br/>
· 膳食纤维主要来自天然的蔬菜、水果、谷类及豆类。蔬菜中的十字花科蔬菜（包括花椰菜、芥菜、白菜等）。<br/>
· 黄色和绿色蔬果，以及洋葱、苹果皮等食物中，含有丰富类黄酮素，多吃也有助于预防癌症。<br/><br/>
<style font="fzltchjw" font_size="14" font_color="#607b3f">戒烟</style><br/><br/>
<style font="fzltchjw" font_size="14" font_color="#607b3f">坚持规律锻炼</style><br/><br/>
<style font="fzltchjw" font_size="14" font_color="#607b3f">定期筛查</style><br/>
美国癌症协会建议，从 50 岁开始，所有人都应该选择以下 5 种筛查方案中的一种执行，如果筛查结果为阳性，则需要做结肠镜检查。<br/>
· 每年进行粪便潜血试验（FOBT） 或者是粪便免疫化学试验（FIT）;<br/>
· 每五年乙状结肠镜检查，时间灵活;<br/>
· 每年（FOBT）或（FIT），加上每五年一次时间灵活的乙状结肠镜检查; · 每五年结肠双对比造影;<br/>
· 每十年结肠镜检查。<br/><br/>
<style font="fzltchjw" font_size="14" font_color="#607b3f">高危人群</style><br/>
有炎症性肠道疾病或有结肠癌家族史的人群应该尽早就医，遵医嘱进行相关检查并随诊。<br/><br/>
<style font_size="11" font_color="#738c34" bold="true">经幸福基石的特约医生对您进行包括个人健康状况、家族史等全面评估后，会给出更具体建议，请遵照医生咨询后的建议。</style>
]]>
        </parameter>
        <table id="gaiShuZhiBingJiYinLieBiao">
            <headers>
                <header column="0" value="基因"/>
                <header column="1" value="突变位置"/>
                <header column="2" value="类型"/>
                <header column="3" value="致病性证据 *"/>
                <header column="4" value="人群频率 **"/>
            </headers>
            <rows>
                <cell row="0" column="0" value="MUTYH"/>
                <cell row="0" column="1" value="NM_001128425.1:c.934-2A>G"/>
                <cell row="0" column="2" value="杂合，可变剪切位点突变 splice acceptor variant"/>
                <cell row="0" column="3" value="Likely pathogenic（2 例）; Probably pathogencic（1 例）"/>
                <cell row="0" column="4" value="1%"/>

                <cell row="1" column="0" value="FAT3"/>
                <cell row="1" column="1" value="NM_001008781:exon9:c.A8263G:p.I2755V"/>
                <cell row="1" column="2" value="纯和，非同义突变"/>
                <cell row="1" column="3" value="无"/>
                <cell row="1" column="4" value="14%"/>
            </rows>
        </table>
        <table id="gaiShuJiYinFengXianPingFen">
            <headers>
                <header column="0" value="疾病"/>
                <header column="1" value="您的结果"/>
                <header column="2" value="相对风险评分"/>
                <header column="3" value="详解页码"/>
            </headers>
            <rows>
                <cell row="0"  column="0" value="乳腺癌"/>
                <cell row="1"  column="0" value="结直肠癌"/>
                <cell row="2"  column="0" value="甲状腺癌"/>
                <cell row="3"  column="0" value="子宫颈癌"/>

                <cell row="0"  column="1" value="4.76"/>
                <cell row="1"  column="1" value="4.41"/>
                <cell row="2"  column="1" value="2.19"/>
                <cell row="3"  column="1" value="1.14"/>

                <cell row="0"  column="2" value="1.46"/>
                <cell row="1"  column="2" value="1.41"/>
                <cell row="2"  column="2" value="1.19"/>
                <cell row="3"  column="2" value="1.14"/>

                <cell row="0"  column="3" value="4 1 0"/>
                <cell row="1"  column="3" value="4 2 0"/>
                <cell row="2"  column="3" value="4 3 0"/>
                <cell row="3"  column="3" value="4 4 0"/>
            </rows>
        </table>


















        <group order="1" id="catalog_4_1" value="4 1" catalog="4 1">
            <parameter id="detailJiBing" value="乳腺癌"/>
            <parameter id="detailJiBingEnglish" value="Mammary Cancer"/>
            <parameter id="detailZhibingjiyinJianChu" value="">
                <![CDATA[基因名词：<style italic="true">MUTYH</style> <br/> 该基因突变的可致疾病：直结肠癌 家族性腺瘤性息肉病 <br/>]]>
            </parameter>
            <parameter id="detailFengXianJiYinPingFen" value="0.98"/>
            <parameter id="detailFengXianJiYinPingFenMiaoShu" value="与东亚人群相比，您患肺癌的相对风险降低 63.36%，是普通人的 0.37 倍。"/>
            <parameter id="detailRenQunPingJunFaBingLv" value="0.0280%"/>
            <parameter id="detailGeRenFaBingLv" value="0.0103%"/>
            <parameter id="detailJiBingGaiShu" value="">
<![CDATA[肺癌是发病率和死亡率增长最快，对人群健康和生命威胁最大的恶性肿瘤之一。近年来肺癌的发病率和死亡率均明显增高，男性肺癌发病率和死亡率均占所有恶性肿瘤的第 一位，女性发病率和死亡率占第二位。<br/>
长期大量吸烟与肺癌的发生有非常密切的关系。已长期大量吸烟者患肺癌的概率是不吸烟者的 10 ~ 20 倍，开始吸烟的年龄越小，患肺癌的几 率越高。被动吸烟者肺癌患病率也明显增加。<br/>
城市居民肺癌的发病率比农村高，可能与城市大气污染和烟尘中含有致癌物质有关。<br/><br/>
 <style font="fzltchjw" font_color="#607b3f" font_size="14">危害因素</style><br/>
 <style font_color="#607b3f" font_size="5">______________________________________________________________________________</style><br/><br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">吸烟：</style> <br/>
目前认为吸烟是肺癌的最重要的高危因素。烟草中有超过 3000 种化学物质，其中多链芳香烃类化合物（如：苯并芘）和 亚硝胺均有很强的致癌活性。<br/><br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">职业和环境接触：</style> <br/>
肺癌是职业癌中最重要的一种。估约 10% 的肺癌患者有环境和职业接触史。<br/>
· 现已证明以下9种职业环境致癌物增加肺癌的发生率：铝制品的副产品、砷、石棉、bis-chloromethylether、铬化合物、 焦炭炉、芥子气、含镍的杂质、氯乙烯。<br/> 
· 长期接触铍、镉、硅、福尔马林等物质也会增加肺癌的发病率。<br/> 
· 煤气、沥青、炼焦工人肺癌发病率较一般人群为高。<br/> 
· 空气污染，特别是工业废气均能引发肺癌。<br/> <br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">电离辐射：</style> <br/>
肺脏是对放射线较为敏感的器官。美国曾有报道开采放射性矿石的矿工 70% ~ 80% 死于放射引起的职业性肺癌。日本原子弹爆炸幸存者中患肺癌者显著增加。距爆心距离越近，其死于肺癌者明显增加。<br/><br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">既往肺部慢性感染：</style><br/>
 如肺结核、支气管扩张症等患者，支气管上皮在慢性感染过程中可能化生为鳞状上皮致使癌变，但较为少见。<br/>  <br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">遗传因素：</style> <br/>
· 遗传因素（家族聚集、遗传易感性）可能在对环境致癌物易感的人群和/或个体中起重要作用。<br/> 
 · 免疫功能降低，代谢、内分泌功能失调等也可能在肺癌的发生中起重要作用。<br/><br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">大气污染：</style><br/>
发达国家肺癌的发病率高，主要原因是由于含有苯并芘致癌烃等有害物质污染大气有关。大气污染与吸烟对肺癌的发病率 可能互相促进，起协同作用。<br/><br/>
 <style font="fzltchjw" font_color="#607b3f" font_size="14">高危人群</style> <br/>
<style font_color="#607b3f" font_size="5">______________________________________________________________________________</style><br/><br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">（a）</style>40 岁以上的长期吸烟者（开始吸烟的年龄愈小，吸烟年数愈多，吸烟量愈大，则危险愈大）<br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">（b）</style>经常接触煤烟或油烟者<br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">（c）</style>有过量放射线照射者 <br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">（d）</style>职业上接触无机砷、石棉、铬、镍等的人 <br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">（e）</style>慢性肺部疾病患者：如慢性支气管炎、肺结核等 <br/><br/>
<style font="fzltchjw" font_color="#607b3f" font_size="14">如何预防</style> <br/>
<style font_color="#607b3f" font_size="5">______________________________________________________________________________</style> <br/><br/>
肺癌是可以预防的。在生活中注意以下方面，做到有效预防。<br/><br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">远离烟草：</style> <br/>
烟民在指导下制定戒烟计划。拒绝二手烟污染，特别要警惕三手烟对婴幼儿和青少年的健康危害! <br/><br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">室内油烟污染：</style> <br/>
包括北方地区取暖和烧饭的燃煤污染、城市居民烹调产生的油烟危害，特别是没有科学正确地使用厨房抽油烟机。 <br/><br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">新居乔迁及装修：</style> <br/>
 修材料和漆料一定要选购绿色合格产品，不要使用含氡量高的建筑和装修材料。在装修结束入住以前，要请当地环保部门验收合格后再入住。 <br/><br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">减少大气污染的暴露，远离水污染：</style> <br/>
大气污染、沉降指数、烟雾指数、苯并芘等暴露剂量与肺癌的发生率成正相关关系。 <br/><br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">避免职业和环境致癌因素：</style> <br/>
 重视职业保护和职业病防治。在主要重工业地区、煤矿和金属矿区、石油和石化地区、核工业基地等地区，每年需进行一次体检或肺癌筛查。 <br/><br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">保持心情愉快：</style> <br/>
特别是那些长期性格内向、性情孤僻和处于郁闷心情状态的中老年人。要善于同人沟通，苦闷烦躁时尤为重要。症状严重时要及时到心理科医生寻求帮助，必要时接受心理治疗和药物治疗。 <br/><br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">有肺癌家族史的人：</style> <br/>
重视健康体检和防癌体检，每年定期体检中需要加做防癌检查项目，如进行胸部 CT 扫描检查等。 <br/><br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">健康的生活方式：</style> <br/>
不吸烟，不酗酒，注意规律饮食和睡眠，加强身体锻炼。 <br/><br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">科学饮食：</style> <br/>
增加饮食中蔬菜、水果等可以预防肺癌。  <br/><br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">重视癌前病变的治疗：</style> <br/>
 既往有肺结核、肺部炎症病史者要定期到专科医院就诊和规范治疗。<br/>]]>
            </parameter>
            <parameter id="detailCanKaoWenXian" value="">
<![CDATA[1. Bogdanova, N. et al. Association of two mutations in the CHEK2 gene with breast cancer. Int J Cancer 116, 263-6 (2005).
<br/><br/>2. Cai, Q. et al. Genome-wide association study identifies breast cancer risk variant at 10q21.2: results from the Asia Breast Cancer Consortium. Hum Mol Genet 20, 4991-9 (2011).
<br/><br/>3. Cai, Q. et al. Genome-wide association analysis in East Asians identifies breast cancer susceptibility loci at 1q32.1, 5q14.3 and 15q26.1. Nat Genet 46, 886-90 (2014).
<br/><br/>4. Chen, F. et al. A genome-wide association study of breast cancer in women of African ancestry. Hum Genet 132, 39-48 (2013).
<br/><br/>5. Chen, J.J., Silver, D., Cantor, S., Livingston, D.M. &amp; Scully, R. BRCA1, BRCA2, and Rad51 operate in a common DNA damage response pathway. Cancer Res 59, 1752s-1756s (1999).
<br/><br/>6. Easton, D.F. et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447, 1087-93 (2007).
<br/><br/>7. Elgazzar, S. et al. A genome-wide association study identifies a genetic variant in the SIAH2 locus associated with hormonal receptor-positive breast cancer in Japanese. J Hum Genet 57, 766-71 (2012).
<br/><br/>8. Fletcher, O. et al. Novel breast cancer susceptibility locus at 9q31.2: results of a genome-wide association study. J Natl Cancer Inst 103, 425-35 (2011).
<br/><br/>9. Frank, B. et al. BRIP1 (BACH1) variants and familial breast cancer risk: a case-control study. BMC Cancer 7, 83 (2007).
<br/><br/>10. Fukuda, T. et al. Alterations of the double-strand break repair gene MRE11 in cancer. Cancer Res 61, 23-6 (2001).
<br/><br/>11. Garcia-Closas, M. et al. Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet 45, 392-8, 398e1-2 (2013).
<br/><br/>12. Kim, H.C. et al. A genome-wide association study identifies a breast cancer risk variant in ERBB4 at 2q34: results from the Seoul Breast Cancer Study. Breast Cancer Res 14, R56 (2012).
<br/><br/>13. Li, J. et al. A combined analysis of genome-wide association studies in breast cancer. Breast Cancer Res Treat 126, 717-27 (2011).
<br/><br/>14. Long, J. et al. Identification of a functional genetic variant at 16q12.1 for breast cancer risk: results from the Asia Breast Cancer Consortium. PLoS Genet 6, e1001002 (2010).
<br/><br/>15. Long, J. et al. Genome-wide association study in east Asians identifies novel susceptibility loci for breast cancer. PLoS Genet 8, e1002532 (2012).
<br/><br/>16. Lynch, E.D. et al. Inherited mutations in PTEN that are associated with breast cancer, cowden disease, and juvenile polyposis. Am J Hum Genet 61, 1254-60 (1997).
<br/><br/>17. Masciari, S. et al. Germline E-cadherin mutations in familial lobular breast cancer. J Med Genet 44, 726-31 (2007).
<br/><br/>18. Merino, D. &amp; Malkin, D. p53 and hereditary cancer. Subcell Biochem 85, 1-16 (2014).
<br/><br/>19. Michailidou, K. et al. Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet 45, 353-61, 361e1-2 (2013).
<br/><br/>20. Milne, R.L. Variants in the ATM gene and breast cancer susceptibility. Genome Med 1, 12 (2009).
<br/><br/>21. Monsees, G.M., Kraft, P., Chanock, S.J., Hunter, D.J. &amp; Han, J. Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk. Breast Cancer Res Treat 125, 207-14 (2011).
<br/><br/>22. Rebbeck, T.R. et al. Genetic heterogeneity in hereditary breast cancer: role of BRCA1 and BRCA2. Am J Hum Genet 59, 547-53 (1996).
<br/><br/>23. Rennert, G. et al. MutYH mutation carriers have increased breast cancer risk. Cancer 118, 1989-93 (2012). 24. Rinella, E.S. et al. Genetic variants associated with breast cancer risk for Ashkenazi Jewish women with strong family histories but no identifiable BRCA1/2 mutation. Hum Genet 132, 523-36 (2013).
<br/><br/>25. Siddiq, A. et al. A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. Hum Mol Genet 21, 5373-84 (2012).
<br/><br/>26. Song, C. et al. A genome-wide scan for breast cancer risk haplotypes among African American women. PLoS One 8, e57298 (2013).
<br/><br/>27. Stone, J.G. et al. Contribution of germline MLH1 and MSH2 mutations to lobular carcinoma in situ of the breast. Cancer Lett 167, 171-4 (2001).
<br/><br/>28. Thai, T.H. et al. Mutations in the BRCA1-associated RING domain (BARD1) gene in primary breast, ovarian and uterine cancers. Hum Mol Genet 7, 195-202 (1998).
<br/><br/>29. Tischkowitz, M. et al. Rare germline mutations in PALB2 and breast cancer risk: a population-based study. Hum Mutat 33, 674-80 (2012).
<br/><br/>30. Turnbull, C. et al. Genome-wide association study identifies five new breast cancer susceptibility loci. Nat Genet 42, 504-7 (2010).
<br/><br/>31. Walsh, T. &amp; King, M.C. Ten genes for inherited breast cancer. Cancer Cell 11, 103-5 (2007).
<br/><br/>32. Zheng, W. et al. Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1. Nat Genet 41, 324-8 (2009).
]]>
            </parameter>
            <table id="detailZhiBingJiYinTuBian">
                <headers>
                    <header column="0" value="基因"/>
                    <header column="1" value="突变位置"/>
                    <header column="2" value="类型"/>
                    <header column="3" value="致病性证据 *"/>
                    <header column="4" value="人群频率 **"/>
                </headers>
                <rows>
                    <cell row="0" column="0" value="MUTYH"/>
                    <cell row="0" column="1" value="NM_001128425.1:c.934-2A>G"/>
                    <cell row="0" column="2" value="杂合，可变剪切位点突变 splice acceptor variant"/>
                    <cell row="0" column="3" value="Likely pathogenic（2 例）; Probably pathogencic（1 例）"/>
                    <cell row="0" column="4" value="1%"/>
                </rows>
            </table>
            <table id="detailZhiBingJiYinLieBiao">
                <headers>
                    <header column="0" value="基因名称"/>
                    <header column="1" value="检测点位数"/>
                    <header column="2" value="变异点位"/>
                    <header column="3" value="检测结果"/>
                </headers>
                <rows>
                    <cell row="0"  column="0" value="ATM"/>
                    <cell row="1"  column="0" value="BARD1"/>
                    <cell row="2"  column="0" value="BRCA1"/>
                    <cell row="3"  column="0" value="BRCA2"/>
                    <cell row="4"  column="0" value="BRIP1"/>
                    <cell row="5"  column="0" value="CDH1"/>
                    <cell row="6"  column="0" value="CHEK2"/>

                    <cell row="0"  column="1" value="150"/>
                    <cell row="1"  column="1" value="14"/>
                    <cell row="2"  column="1" value="320"/>
                    <cell row="3"  column="1" value="382"/>
                    <cell row="4"  column="1" value="37"/>
                    <cell row="5"  column="1" value="9"/>
                    <cell row="6"  column="1" value="40"/>

                    <cell row="0"  column="2" value="无"/>
                    <cell row="1"  column="2" value="无"/>
                    <cell row="2"  column="2" value="rs77542170"/>
                    <cell row="3"  column="2" value="无"/>
                    <cell row="4"  column="2" value="rs77542170"/>
                    <cell row="5"  column="2" value="无"/>
                    <cell row="6"  column="2" value="无"/>

                    <cell row="0"  column="3" value="（-）"/>
                    <cell row="1"  column="3" value="（-）"/>
                    <cell row="2"  column="3" value="（+）"/>
                    <cell row="3"  column="3" value="（-）"/>
                    <cell row="4"  column="3" value="（+）"/>
                    <cell row="5"  column="3" value="（-）"/>
                    <cell row="6"  column="3" value="（-）"/>
                </rows>
            </table>
            <table id="detailFengXianJiYinLieBiao">
                <headers>
                    <header column="0" value="基因点位"/>
                    <header column="1" value="参考等位基因"/>
                    <header column="2" value="风险等位基因"/>
                    <header column="3" value="个人基因型检出结果"/>
                    <header column="4" value="相对风险值"/>
                </headers>
                <rows>
                    <cell row="0"   column="0" value="rs000000001"/>
                    <cell row="1"   column="0" value="rs000000002"/>
                    <cell row="2"   column="0" value="rs000000003"/>
                    <cell row="3"   column="0" value="rs000000004"/>
                    <cell row="4"   column="0" value="rs000000005"/>
                    <cell row="5"   column="0" value="rs000000006"/>
                    <cell row="6"   column="0" value="rs000000008"/>
                    <cell row="7"   column="0" value="rs000000009"/>
                    <cell row="8"   column="0" value="rs000000010"/>
                    <cell row="9"   column="0" value="rs000000011"/>
                    <cell row="10"  column="0" value="rs000000012"/>
                    <cell row="11"  column="0" value="rs000000013"/>
                    <cell row="12"  column="0" value="rs000000014"/>
                    <cell row="13"  column="0" value="rs000000015"/>
                    <cell row="14"  column="0" value="rs000000016"/>
                    <cell row="15"  column="0" value="rs000000017"/>
                    <cell row="16"  column="0" value="rs000000018"/>
                    <cell row="17"  column="0" value="rs000000019"/>
                    <cell row="18"  column="0" value="rs000000020"/>
                    <cell row="19"  column="0" value="rs000000021"/>
                    <cell row="20"  column="0" value="rs000000022"/>
                    <cell row="21"  column="0" value="rs000000023"/>
                    <cell row="22"  column="0" value="rs000000024"/>
                    <cell row="23"  column="0" value="rs000000025"/>
                    <cell row="24"  column="0" value="rs000000026"/>
                    <cell row="25"  column="0" value="rs000000027"/>
                    <cell row="26"  column="0" value="rs000000028"/>
                    <cell row="27"  column="0" value="rs000000029"/>

                    <cell row="0"   column="1" value="C"/>
                    <cell row="1"   column="1" value="C"/>
                    <cell row="2"   column="1" value="G"/>
                    <cell row="3"   column="1" value="T"/>
                    <cell row="4"   column="1" value="C"/>
                    <cell row="5"   column="1" value="T"/>
                    <cell row="6"   column="1" value="C"/>
                    <cell row="7"   column="1" value="A"/>
                    <cell row="8"   column="1" value="A"/>
                    <cell row="9"   column="1" value="C"/>
                    <cell row="10"  column="1" value="A"/>
                    <cell row="11"  column="1" value="A"/>
                    <cell row="12"  column="1" value="C"/>
                    <cell row="13"  column="1" value="C"/>
                    <cell row="14"  column="1" value="A"/>
                    <cell row="15"  column="1" value="C"/>
                    <cell row="16"  column="1" value="A"/>
                    <cell row="17"  column="1" value="T"/>
                    <cell row="18"  column="1" value="A"/>
                    <cell row="19"  column="1" value="A"/>
                    <cell row="20"  column="1" value="C"/>
                    <cell row="21"  column="1" value="C"/>
                    <cell row="22"  column="1" value="A"/>
                    <cell row="23"  column="1" value="A"/>
                    <cell row="24"  column="1" value="A"/>
                    <cell row="25"  column="1" value="T"/>
                    <cell row="26"  column="1" value="T"/>
                    <cell row="27"  column="1" value="A"/>

                    <cell row="0"   column="2" value="C"/>
                    <cell row="1"   column="2" value="C"/>
                    <cell row="2"   column="2" value="G"/>
                    <cell row="3"   column="2" value="T"/>
                    <cell row="4"   column="2" value="C"/>
                    <cell row="5"   column="2" value="T"/>
                    <cell row="6"   column="2" value="C"/>
                    <cell row="7"   column="2" value="A"/>
                    <cell row="8"   column="2" value="A"/>
                    <cell row="9"   column="2" value="C"/>
                    <cell row="10"  column="2" value="A"/>
                    <cell row="11"  column="2" value="A"/>
                    <cell row="12"  column="2" value="C"/>
                    <cell row="13"  column="2" value="C"/>
                    <cell row="14"  column="2" value="A"/>
                    <cell row="15"  column="2" value="C"/>
                    <cell row="16"  column="2" value="A"/>
                    <cell row="17"  column="2" value="T"/>
                    <cell row="18"  column="2" value="A"/>
                    <cell row="19"  column="2" value="A"/>
                    <cell row="20"  column="2" value="C"/>
                    <cell row="21"  column="2" value="C"/>
                    <cell row="22"  column="2" value="A"/>
                    <cell row="23"  column="2" value="A"/>
                    <cell row="24"  column="2" value="A"/>
                    <cell row="25"  column="2" value="T"/>
                    <cell row="26"  column="2" value="T"/>
                    <cell row="27"  column="2" value="A"/>

                    <cell row="0"   column="2" value="C"/>
                    <cell row="1"   column="2" value="C"/>
                    <cell row="2"   column="2" value="G"/>
                    <cell row="3"   column="2" value="T"/>
                    <cell row="4"   column="2" value="C"/>
                    <cell row="5"   column="2" value="T"/>
                    <cell row="6"   column="2" value="C"/>
                    <cell row="7"   column="2" value="A"/>
                    <cell row="8"   column="2" value="A"/>
                    <cell row="9"   column="2" value="C"/>
                    <cell row="10"  column="2" value="A"/>
                    <cell row="11"  column="2" value="A"/>
                    <cell row="12"  column="2" value="C"/>
                    <cell row="13"  column="2" value="C"/>
                    <cell row="14"  column="2" value="A"/>
                    <cell row="15"  column="2" value="C"/>
                    <cell row="16"  column="2" value="A"/>
                    <cell row="17"  column="2" value="T"/>
                    <cell row="18"  column="2" value="A"/>
                    <cell row="19"  column="2" value="A"/>
                    <cell row="20"  column="2" value="C"/>
                    <cell row="21"  column="2" value="C"/>
                    <cell row="22"  column="2" value="A"/>
                    <cell row="23"  column="2" value="A"/>
                    <cell row="24"  column="2" value="A"/>
                    <cell row="25"  column="2" value="T"/>
                    <cell row="26"  column="2" value="T"/>
                    <cell row="27"  column="2" value="A"/>

                    <cell row="0"   column="3" value="CC"/>
                    <cell row="1"   column="3" value="CC"/>
                    <cell row="2"   column="3" value="GG"/>
                    <cell row="3"   column="3" value="TT"/>
                    <cell row="4"   column="3" value="CC"/>
                    <cell row="5"   column="3" value="TT"/>
                    <cell row="6"   column="3" value="CC"/>
                    <cell row="7"   column="3" value="AA"/>
                    <cell row="8"   column="3" value="AA"/>
                    <cell row="9"   column="3" value="CC"/>
                    <cell row="10"  column="3" value="AA"/>
                    <cell row="11"  column="3" value="AA"/>
                    <cell row="12"  column="3" value="CC"/>
                    <cell row="13"  column="3" value="CC"/>
                    <cell row="14"  column="3" value="AA"/>
                    <cell row="15"  column="3" value="CC"/>
                    <cell row="16"  column="3" value="AA"/>
                    <cell row="17"  column="3" value="TT"/>
                    <cell row="18"  column="3" value="AA"/>
                    <cell row="19"  column="3" value="AA"/>
                    <cell row="20"  column="3" value="CC"/>
                    <cell row="21"  column="3" value="CC"/>
                    <cell row="22"  column="3" value="AA"/>
                    <cell row="23"  column="3" value="AA"/>
                    <cell row="24"  column="3" value="AA"/>
                    <cell row="25"  column="3" value="TT"/>
                    <cell row="26"  column="3" value="TT"/>
                    <cell row="27"  column="3" value="AA"/>

                    <cell row="0"   column="4" value="0.95"/>
                    <cell row="1"   column="4" value="0.95"/>
                    <cell row="2"   column="4" value="0.95"/>
                    <cell row="3"   column="4" value="0.95"/>
                    <cell row="4"   column="4" value="0.95"/>
                    <cell row="5"   column="4" value="0.95"/>
                    <cell row="6"   column="4" value="0.95"/>
                    <cell row="7"   column="4" value="0.95"/>
                    <cell row="8"   column="4" value="0.95"/>
                    <cell row="9"   column="4" value="0.95"/>
                    <cell row="10"  column="4" value="0.95"/>
                    <cell row="11"  column="4" value="0.95"/>
                    <cell row="12"  column="4" value="0.95"/>
                    <cell row="13"  column="4" value="0.95"/>
                    <cell row="14"  column="4" value="0.95"/>
                    <cell row="15"  column="4" value="0.95"/>
                    <cell row="16"  column="4" value="0.95"/>
                    <cell row="17"  column="4" value="0.95"/>
                    <cell row="18"  column="4" value="0.95"/>
                    <cell row="19"  column="4" value="0.95"/>
                    <cell row="20"  column="4" value="0.95"/>
                    <cell row="21"  column="4" value="0.95"/>
                    <cell row="22"  column="4" value="0.95"/>
                    <cell row="23"  column="4" value="0.95"/>
                    <cell row="24"  column="4" value="0.95"/>
                    <cell row="25"  column="4" value="0.95"/>
                    <cell row="26"  column="4" value="0.95"/>
                    <cell row="27"  column="4" value="0.95"/>
                </rows>
            </table>
            <table id="detailJianKangGuanLiCuoShi">
                <headers>
                    <header column="0" value="措施icon"/>
                    <header column="1" value="措施"/>
                </headers>
                <rows>
                    <cell row="0"   column="0" value="/Users/zhaolisong/Desktop/projects/cooltoo/parse_pdf/templates/template_medicine_selected/measure_header.jpg"/>
                    <cell row="1"   column="0" value="/Users/zhaolisong/Desktop/projects/cooltoo/parse_pdf/templates/template_medicine_selected/measure_header.jpg"/>
                    <cell row="2"   column="0" value="/Users/zhaolisong/Desktop/projects/cooltoo/parse_pdf/templates/template_medicine_selected/measure_header.jpg"/>
                    <cell row="3"   column="0" value="/Users/zhaolisong/Desktop/projects/cooltoo/parse_pdf/templates/template_medicine_selected/measure_header.jpg"/>
                    <cell row="4"   column="0" value="/Users/zhaolisong/Desktop/projects/cooltoo/parse_pdf/templates/template_medicine_selected/measure_header.jpg"/>
                    <cell row="5"   column="0" value="/Users/zhaolisong/Desktop/projects/cooltoo/parse_pdf/templates/template_medicine_selected/measure_header.jpg"/>
                    <cell row="6"   column="0" value="/Users/zhaolisong/Desktop/projects/cooltoo/parse_pdf/templates/template_medicine_selected/measure_header.jpg"/>
                    <cell row="7"   column="0" value="/Users/zhaolisong/Desktop/projects/cooltoo/parse_pdf/templates/template_medicine_selected/measure_header.jpg"/>
                    <cell row="8"   column="0" value="/Users/zhaolisong/Desktop/projects/cooltoo/parse_pdf/templates/template_medicine_selected/measure_header.jpg"/>

                    <cell row="0"   column="1" value="">
    <![CDATA[<style font_color="#607b3f" font_size="14" bold="true">减肥：</style> <br/> <br/>
    控制体重，尤其是避免绝经后肥胖]]>
                    </cell>
                    <cell row="1"   column="1" value="">
    <![CDATA[<style font_color="#607b3f" font_size="14" bold="true">减肥：</style> <br/> <br/>
    控制体重，尤其是避免绝经后肥胖尤其是避免绝经后肥胖尤其是避免绝经后肥胖]]>
                    </cell>
                    <cell row="2"   column="1" value="">
    <![CDATA[<style font_color="#607b3f" font_size="14" bold="true">减肥：</style> <br/> <br/>
    控制体重，尤其是避免绝经后肥胖尤其是避免绝经后肥胖尤其是避免绝经后肥胖]]>
                    </cell>
                    <cell row="3"   column="1" value="">
    <![CDATA[<style font_color="#607b3f" font_size="14" bold="true">减肥：</style> <br/> <br/>
    控制体重，尤其是避免绝经后肥胖尤其是避免绝经后肥胖尤其是避免绝经后肥胖]]>
                    </cell>
                    <cell row="4"   column="1" value="">
    <![CDATA[<style font_color="#607b3f" font_size="14" bold="true">减肥：</style> <br/> <br/>
    控制体重，尤其是避免绝经后肥胖尤其是避免绝经后肥胖尤其是避免绝经后肥胖]]>
                    </cell>
                    <cell row="5"   column="1" value="">
    <![CDATA[<style font_color="#607b3f" font_size="14" bold="true">减肥：</style> <br/> <br/>
    控制体重，尤其是避免绝经后肥胖尤其是避免绝经后肥胖尤其是避免绝经后肥胖]]>
                    </cell>
                    <cell row="6"   column="1" value="">
    <![CDATA[<style font_color="#607b3f" font_size="14" bold="true">减肥：</style> <br/> <br/>
    控制体重，尤其是避免绝经后肥胖尤其是避免绝经后肥胖尤其是避免绝经后肥胖]]>
                    </cell>
                    <cell row="7"   column="1" value="">
    <![CDATA[<style font_color="#607b3f" font_size="14" bold="true">减肥：</style> <br/> <br/>
    控制体重，尤其是避免绝经后肥胖尤其是避免绝经后肥胖尤其是避免绝经后肥胖]]>
                    </cell>
                    <cell row="8"   column="1" value="">
    <![CDATA[<style font_color="#607b3f" font_size="14" bold="true">减肥：</style> <br/> <br/>
    控制体重，尤其是避免绝经后肥胖尤其是避免绝经后肥胖尤其是避免绝经后肥胖]]>
                    </cell>
                </rows>
            </table>
        </group>








        <group order="2" id="catalog_4_2" value="4 2" catalog="4 2">
            <parameter id="detailJiBing" value="肺癌"/>
            <parameter id="detailJiBingEnglish" value="Mammary Cancer"/>
            <parameter id="detailZhibingjiyinJianChu" value="">
                <![CDATA[基因名词：<style italic="true">MUTYH</style> <br/> 该基因突变的可致疾病：肺癌 家族性腺瘤性息肉病 <br/>]]>
            </parameter>
            <parameter id="detailFengXianJiYinPingFen" value="0.98"/>
            <parameter id="detailFengXianJiYinPingFenMiaoShu" value="与东亚人群相比，您患肺癌的相对风险降低 63.36%，是普通人的 0.37 倍。"/>
            <parameter id="detailRenQunPingJunFaBingLv" value="0.0280%"/>
            <parameter id="detailGeRenFaBingLv" value="0.0103%"/>
            <parameter id="detailJiBingGaiShu" value="">
                <![CDATA[肺癌是发病率和死亡率增长最快，对人群健康和生命威胁最大的恶性肿瘤之一。近年来肺癌的发病率和死亡率均明显增高，男性肺癌发病率和死亡率均占所有恶性肿瘤的第 一位，女性发病率和死亡率占第二位。<br/>
长期大量吸烟与肺癌的发生有非常密切的关系。已长期大量吸烟者患肺癌的概率是不吸烟者的 10 ~ 20 倍，开始吸烟的年龄越小，患肺癌的几 率越高。被动吸烟者肺癌患病率也明显增加。<br/>
城市居民肺癌的发病率比农村高，可能与城市大气污染和烟尘中含有致癌物质有关。<br/><br/>
 <style font="fzltchjw" font_color="#607b3f" font_size="14">危害因素</style><br/>
 <style font_color="#607b3f" font_size="5">______________________________________________________________________________</style><br/><br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">吸烟：</style> <br/>
目前认为吸烟是肺癌的最重要的高危因素。烟草中有超过 3000 种化学物质，其中多链芳香烃类化合物（如：苯并芘）和 亚硝胺均有很强的致癌活性。<br/><br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">职业和环境接触：</style> <br/>
肺癌是职业癌中最重要的一种。估约 10% 的肺癌患者有环境和职业接触史。<br/>
· 现已证明以下9种职业环境致癌物增加肺癌的发生率：铝制品的副产品、砷、石棉、bis-chloromethylether、铬化合物、 焦炭炉、芥子气、含镍的杂质、氯乙烯。<br/> 
· 长期接触铍、镉、硅、福尔马林等物质也会增加肺癌的发病率。<br/> 
· 煤气、沥青、炼焦工人肺癌发病率较一般人群为高。<br/> 
· 空气污染，特别是工业废气均能引发肺癌。<br/> <br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">电离辐射：</style> <br/>
肺脏是对放射线较为敏感的器官。美国曾有报道开采放射性矿石的矿工 70% ~ 80% 死于放射引起的职业性肺癌。日本原子弹爆炸幸存者中患肺癌者显著增加。距爆心距离越近，其死于肺癌者明显增加。<br/><br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">既往肺部慢性感染：</style><br/>
 如肺结核、支气管扩张症等患者，支气管上皮在慢性感染过程中可能化生为鳞状上皮致使癌变，但较为少见。<br/>  <br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">遗传因素：</style> <br/>
· 遗传因素（家族聚集、遗传易感性）可能在对环境致癌物易感的人群和/或个体中起重要作用。<br/> 
 · 免疫功能降低，代谢、内分泌功能失调等也可能在肺癌的发生中起重要作用。<br/><br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">大气污染：</style><br/>
发达国家肺癌的发病率高，主要原因是由于含有苯并芘致癌烃等有害物质污染大气有关。大气污染与吸烟对肺癌的发病率 可能互相促进，起协同作用。<br/><br/>
 <style font="fzltchjw" font_color="#607b3f" font_size="14">高危人群</style> <br/>
 <style font_color="#607b3f" font_size="5">______________________________________________________________________________</style><br/><br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">（a）</style>40 岁以上的长期吸烟者（开始吸烟的年龄愈小，吸烟年数愈多，吸烟量愈大，则危险愈大）<br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">（b）</style>经常接触煤烟或油烟者<br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">（c）</style>有过量放射线照射者 <br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">（d）</style>职业上接触无机砷、石棉、铬、镍等的人 <br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">（e）</style>慢性肺部疾病患者：如慢性支气管炎、肺结核等 <br/><br/>
<style font="fzltchjw" font_color="#607b3f" font_size="14">如何预防</style> <br/>
 <style font_color="#607b3f" font_size="5">______________________________________________________________________________</style><br/><br/>
肺癌是可以预防的。在生活中注意以下方面，做到有效预防。<br/><br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">远离烟草：</style> <br/>
烟民在指导下制定戒烟计划。拒绝二手烟污染，特别要警惕三手烟对婴幼儿和青少年的健康危害! <br/><br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">室内油烟污染：</style> <br/>
包括北方地区取暖和烧饭的燃煤污染、城市居民烹调产生的油烟危害，特别是没有科学正确地使用厨房抽油烟机。 <br/><br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">新居乔迁及装修：</style> <br/>
 修材料和漆料一定要选购绿色合格产品，不要使用含氡量高的建筑和装修材料。在装修结束入住以前，要请当地环保部门验收合格后再入住。 <br/><br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">减少大气污染的暴露，远离水污染：</style> <br/>
大气污染、沉降指数、烟雾指数、苯并芘等暴露剂量与肺癌的发生率成正相关关系。 <br/><br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">避免职业和环境致癌因素：</style> <br/>
 重视职业保护和职业病防治。在主要重工业地区、煤矿和金属矿区、石油和石化地区、核工业基地等地区，每年需进行一次体检或肺癌筛查。 <br/><br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">保持心情愉快：</style> <br/>
特别是那些长期性格内向、性情孤僻和处于郁闷心情状态的中老年人。要善于同人沟通，苦闷烦躁时尤为重要。症状严重时要及时到心理科医生寻求帮助，必要时接受心理治疗和药物治疗。 <br/><br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">有肺癌家族史的人：</style> <br/>
重视健康体检和防癌体检，每年定期体检中需要加做防癌检查项目，如进行胸部 CT 扫描检查等。 <br/><br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">健康的生活方式：</style> <br/>
不吸烟，不酗酒，注意规律饮食和睡眠，加强身体锻炼。 <br/><br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">科学饮食：</style> <br/>
增加饮食中蔬菜、水果等可以预防肺癌。  <br/><br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">重视癌前病变的治疗：</style> <br/>
 既往有肺结核、肺部炎症病史者要定期到专科医院就诊和规范治疗。<br/>]]>
            </parameter>
            <parameter id="detailCanKaoWenXian" value="">
                <![CDATA[1. Bogdanova, N. et al. Association of two mutations in the CHEK2 gene with breast cancer. Int J Cancer 116, 263-6 (2005).
<br/><br/>2. Cai, Q. et al. Genome-wide association study identifies breast cancer risk variant at 10q21.2: results from the Asia Breast Cancer Consortium. Hum Mol Genet 20, 4991-9 (2011).
<br/><br/>3. Cai, Q. et al. Genome-wide association analysis in East Asians identifies breast cancer susceptibility loci at 1q32.1, 5q14.3 and 15q26.1. Nat Genet 46, 886-90 (2014).
<br/><br/>4. Chen, F. et al. A genome-wide association study of breast cancer in women of African ancestry. Hum Genet 132, 39-48 (2013).
<br/><br/>5. Chen, J.J., Silver, D., Cantor, S., Livingston, D.M. &amp; Scully, R. BRCA1, BRCA2, and Rad51 operate in a common DNA damage response pathway. Cancer Res 59, 1752s-1756s (1999).
<br/><br/>6. Easton, D.F. et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447, 1087-93 (2007).
<br/><br/>7. Elgazzar, S. et al. A genome-wide association study identifies a genetic variant in the SIAH2 locus associated with hormonal receptor-positive breast cancer in Japanese. J Hum Genet 57, 766-71 (2012).
<br/><br/>8. Fletcher, O. et al. Novel breast cancer susceptibility locus at 9q31.2: results of a genome-wide association study. J Natl Cancer Inst 103, 425-35 (2011).
<br/><br/>9. Frank, B. et al. BRIP1 (BACH1) variants and familial breast cancer risk: a case-control study. BMC Cancer 7, 83 (2007).
<br/><br/>10. Fukuda, T. et al. Alterations of the double-strand break repair gene MRE11 in cancer. Cancer Res 61, 23-6 (2001).
<br/><br/>11. Garcia-Closas, M. et al. Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet 45, 392-8, 398e1-2 (2013).
<br/><br/>12. Kim, H.C. et al. A genome-wide association study identifies a breast cancer risk variant in ERBB4 at 2q34: results from the Seoul Breast Cancer Study. Breast Cancer Res 14, R56 (2012).
<br/><br/>13. Li, J. et al. A combined analysis of genome-wide association studies in breast cancer. Breast Cancer Res Treat 126, 717-27 (2011).
<br/><br/>14. Long, J. et al. Identification of a functional genetic variant at 16q12.1 for breast cancer risk: results from the Asia Breast Cancer Consortium. PLoS Genet 6, e1001002 (2010).
<br/><br/>15. Long, J. et al. Genome-wide association study in east Asians identifies novel susceptibility loci for breast cancer. PLoS Genet 8, e1002532 (2012).
<br/><br/>16. Lynch, E.D. et al. Inherited mutations in PTEN that are associated with breast cancer, cowden disease, and juvenile polyposis. Am J Hum Genet 61, 1254-60 (1997).
<br/><br/>17. Masciari, S. et al. Germline E-cadherin mutations in familial lobular breast cancer. J Med Genet 44, 726-31 (2007).
<br/><br/>18. Merino, D. &amp; Malkin, D. p53 and hereditary cancer. Subcell Biochem 85, 1-16 (2014).
<br/><br/>19. Michailidou, K. et al. Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet 45, 353-61, 361e1-2 (2013).
<br/><br/>20. Milne, R.L. Variants in the ATM gene and breast cancer susceptibility. Genome Med 1, 12 (2009).
<br/><br/>21. Monsees, G.M., Kraft, P., Chanock, S.J., Hunter, D.J. &amp; Han, J. Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk. Breast Cancer Res Treat 125, 207-14 (2011).
<br/><br/>22. Rebbeck, T.R. et al. Genetic heterogeneity in hereditary breast cancer: role of BRCA1 and BRCA2. Am J Hum Genet 59, 547-53 (1996).
<br/><br/>23. Rennert, G. et al. MutYH mutation carriers have increased breast cancer risk. Cancer 118, 1989-93 (2012). 24. Rinella, E.S. et al. Genetic variants associated with breast cancer risk for Ashkenazi Jewish women with strong family histories but no identifiable BRCA1/2 mutation. Hum Genet 132, 523-36 (2013).
<br/><br/>25. Siddiq, A. et al. A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. Hum Mol Genet 21, 5373-84 (2012).
<br/><br/>26. Song, C. et al. A genome-wide scan for breast cancer risk haplotypes among African American women. PLoS One 8, e57298 (2013).
<br/><br/>27. Stone, J.G. et al. Contribution of germline MLH1 and MSH2 mutations to lobular carcinoma in situ of the breast. Cancer Lett 167, 171-4 (2001).
<br/><br/>28. Thai, T.H. et al. Mutations in the BRCA1-associated RING domain (BARD1) gene in primary breast, ovarian and uterine cancers. Hum Mol Genet 7, 195-202 (1998).
<br/><br/>29. Tischkowitz, M. et al. Rare germline mutations in PALB2 and breast cancer risk: a population-based study. Hum Mutat 33, 674-80 (2012).
<br/><br/>30. Turnbull, C. et al. Genome-wide association study identifies five new breast cancer susceptibility loci. Nat Genet 42, 504-7 (2010).
<br/><br/>31. Walsh, T. &amp; King, M.C. Ten genes for inherited breast cancer. Cancer Cell 11, 103-5 (2007).
<br/><br/>32. Zheng, W. et al. Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1. Nat Genet 41, 324-8 (2009).
]]>
            </parameter>
            <table id="detailZhiBingJiYinTuBian">
                <headers>
                    <header column="0" value="基因"/>
                    <header column="1" value="突变位置"/>
                    <header column="2" value="类型"/>
                    <header column="3" value="致病性证据 *"/>
                    <header column="4" value="人群频率 **"/>
                </headers>
                <rows>
                    <cell row="0" column="0" value="MUTYH"/>
                    <cell row="0" column="1" value="NM_001128425.1:c.934-2A>G"/>
                    <cell row="0" column="2" value="杂合，可变剪切位点突变 splice acceptor variant"/>
                    <cell row="0" column="3" value="Likely pathogenic（2 例）; Probably pathogencic（1 例）"/>
                    <cell row="0" column="4" value="1%"/>
                </rows>
            </table>
            <table id="detailZhiBingJiYinLieBiao">
                <headers>
                    <header column="0" value="基因名称"/>
                    <header column="1" value="检测点位数"/>
                    <header column="2" value="变异点位"/>
                    <header column="3" value="检测结果"/>
                </headers>
                <rows>
                    <cell row="0"  column="0" value="ATM"/>
                    <cell row="1"  column="0" value="BARD1"/>
                    <cell row="2"  column="0" value="BRCA1"/>
                    <cell row="3"  column="0" value="BRCA2"/>
                    <cell row="4"  column="0" value="BRIP1"/>
                    <cell row="5"  column="0" value="CDH1"/>
                    <cell row="6"  column="0" value="CHEK2"/>

                    <cell row="0"  column="1" value="150"/>
                    <cell row="1"  column="1" value="14"/>
                    <cell row="2"  column="1" value="320"/>
                    <cell row="3"  column="1" value="382"/>
                    <cell row="4"  column="1" value="37"/>
                    <cell row="5"  column="1" value="9"/>
                    <cell row="6"  column="1" value="40"/>

                    <cell row="0"  column="2" value="无"/>
                    <cell row="1"  column="2" value="无"/>
                    <cell row="2"  column="2" value="rs77542170"/>
                    <cell row="3"  column="2" value="无"/>
                    <cell row="4"  column="2" value="rs77542170"/>
                    <cell row="5"  column="2" value="无"/>
                    <cell row="6"  column="2" value="无"/>

                    <cell row="0"  column="3" value="（-）"/>
                    <cell row="1"  column="3" value="（-）"/>
                    <cell row="2"  column="3" value="（+）"/>
                    <cell row="3"  column="3" value="（-）"/>
                    <cell row="4"  column="3" value="（+）"/>
                    <cell row="5"  column="3" value="（-）"/>
                    <cell row="6"  column="3" value="（-）"/>
                </rows>
            </table>
            <table id="detailFengXianJiYinLieBiao">
                <headers>
                    <header column="0" value="基因点位"/>
                    <header column="1" value="参考等位基因"/>
                    <header column="2" value="风险等位基因"/>
                    <header column="3" value="个人基因型检出结果"/>
                    <header column="4" value="相对风险值"/>
                </headers>
                <rows>
                    <cell row="0"   column="0" value="rs000000001"/>
                    <cell row="1"   column="0" value="rs000000002"/>
                    <cell row="2"   column="0" value="rs000000003"/>
                    <cell row="3"   column="0" value="rs000000004"/>
                    <cell row="4"   column="0" value="rs000000005"/>
                    <cell row="5"   column="0" value="rs000000006"/>
                    <cell row="6"   column="0" value="rs000000008"/>
                    <cell row="7"   column="0" value="rs000000009"/>
                    <cell row="8"   column="0" value="rs000000010"/>
                    <cell row="9"   column="0" value="rs000000011"/>
                    <cell row="10"  column="0" value="rs000000012"/>
                    <cell row="11"  column="0" value="rs000000013"/>
                    <cell row="12"  column="0" value="rs000000014"/>
                    <cell row="13"  column="0" value="rs000000015"/>
                    <cell row="14"  column="0" value="rs000000016"/>
                    <cell row="15"  column="0" value="rs000000017"/>
                    <cell row="16"  column="0" value="rs000000018"/>
                    <cell row="17"  column="0" value="rs000000019"/>
                    <cell row="18"  column="0" value="rs000000020"/>
                    <cell row="19"  column="0" value="rs000000021"/>
                    <cell row="20"  column="0" value="rs000000022"/>
                    <cell row="21"  column="0" value="rs000000023"/>
                    <cell row="22"  column="0" value="rs000000024"/>
                    <cell row="23"  column="0" value="rs000000025"/>
                    <cell row="24"  column="0" value="rs000000026"/>
                    <cell row="25"  column="0" value="rs000000027"/>
                    <cell row="26"  column="0" value="rs000000028"/>
                    <cell row="27"  column="0" value="rs000000029"/>

                    <cell row="0"   column="1" value="C"/>
                    <cell row="1"   column="1" value="C"/>
                    <cell row="2"   column="1" value="G"/>
                    <cell row="3"   column="1" value="T"/>
                    <cell row="4"   column="1" value="C"/>
                    <cell row="5"   column="1" value="T"/>
                    <cell row="6"   column="1" value="C"/>
                    <cell row="7"   column="1" value="A"/>
                    <cell row="8"   column="1" value="A"/>
                    <cell row="9"   column="1" value="C"/>
                    <cell row="10"  column="1" value="A"/>
                    <cell row="11"  column="1" value="A"/>
                    <cell row="12"  column="1" value="C"/>
                    <cell row="13"  column="1" value="C"/>
                    <cell row="14"  column="1" value="A"/>
                    <cell row="15"  column="1" value="C"/>
                    <cell row="16"  column="1" value="A"/>
                    <cell row="17"  column="1" value="T"/>
                    <cell row="18"  column="1" value="A"/>
                    <cell row="19"  column="1" value="A"/>
                    <cell row="20"  column="1" value="C"/>
                    <cell row="21"  column="1" value="C"/>
                    <cell row="22"  column="1" value="A"/>
                    <cell row="23"  column="1" value="A"/>
                    <cell row="24"  column="1" value="A"/>
                    <cell row="25"  column="1" value="T"/>
                    <cell row="26"  column="1" value="T"/>
                    <cell row="27"  column="1" value="A"/>

                    <cell row="0"   column="2" value="C"/>
                    <cell row="1"   column="2" value="C"/>
                    <cell row="2"   column="2" value="G"/>
                    <cell row="3"   column="2" value="T"/>
                    <cell row="4"   column="2" value="C"/>
                    <cell row="5"   column="2" value="T"/>
                    <cell row="6"   column="2" value="C"/>
                    <cell row="7"   column="2" value="A"/>
                    <cell row="8"   column="2" value="A"/>
                    <cell row="9"   column="2" value="C"/>
                    <cell row="10"  column="2" value="A"/>
                    <cell row="11"  column="2" value="A"/>
                    <cell row="12"  column="2" value="C"/>
                    <cell row="13"  column="2" value="C"/>
                    <cell row="14"  column="2" value="A"/>
                    <cell row="15"  column="2" value="C"/>
                    <cell row="16"  column="2" value="A"/>
                    <cell row="17"  column="2" value="T"/>
                    <cell row="18"  column="2" value="A"/>
                    <cell row="19"  column="2" value="A"/>
                    <cell row="20"  column="2" value="C"/>
                    <cell row="21"  column="2" value="C"/>
                    <cell row="22"  column="2" value="A"/>
                    <cell row="23"  column="2" value="A"/>
                    <cell row="24"  column="2" value="A"/>
                    <cell row="25"  column="2" value="T"/>
                    <cell row="26"  column="2" value="T"/>
                    <cell row="27"  column="2" value="A"/>

                    <cell row="0"   column="2" value="C"/>
                    <cell row="1"   column="2" value="C"/>
                    <cell row="2"   column="2" value="G"/>
                    <cell row="3"   column="2" value="T"/>
                    <cell row="4"   column="2" value="C"/>
                    <cell row="5"   column="2" value="T"/>
                    <cell row="6"   column="2" value="C"/>
                    <cell row="7"   column="2" value="A"/>
                    <cell row="8"   column="2" value="A"/>
                    <cell row="9"   column="2" value="C"/>
                    <cell row="10"  column="2" value="A"/>
                    <cell row="11"  column="2" value="A"/>
                    <cell row="12"  column="2" value="C"/>
                    <cell row="13"  column="2" value="C"/>
                    <cell row="14"  column="2" value="A"/>
                    <cell row="15"  column="2" value="C"/>
                    <cell row="16"  column="2" value="A"/>
                    <cell row="17"  column="2" value="T"/>
                    <cell row="18"  column="2" value="A"/>
                    <cell row="19"  column="2" value="A"/>
                    <cell row="20"  column="2" value="C"/>
                    <cell row="21"  column="2" value="C"/>
                    <cell row="22"  column="2" value="A"/>
                    <cell row="23"  column="2" value="A"/>
                    <cell row="24"  column="2" value="A"/>
                    <cell row="25"  column="2" value="T"/>
                    <cell row="26"  column="2" value="T"/>
                    <cell row="27"  column="2" value="A"/>

                    <cell row="0"   column="3" value="CC"/>
                    <cell row="1"   column="3" value="CC"/>
                    <cell row="2"   column="3" value="GG"/>
                    <cell row="3"   column="3" value="TT"/>
                    <cell row="4"   column="3" value="CC"/>
                    <cell row="5"   column="3" value="TT"/>
                    <cell row="6"   column="3" value="CC"/>
                    <cell row="7"   column="3" value="AA"/>
                    <cell row="8"   column="3" value="AA"/>
                    <cell row="9"   column="3" value="CC"/>
                    <cell row="10"  column="3" value="AA"/>
                    <cell row="11"  column="3" value="AA"/>
                    <cell row="12"  column="3" value="CC"/>
                    <cell row="13"  column="3" value="CC"/>
                    <cell row="14"  column="3" value="AA"/>
                    <cell row="15"  column="3" value="CC"/>
                    <cell row="16"  column="3" value="AA"/>
                    <cell row="17"  column="3" value="TT"/>
                    <cell row="18"  column="3" value="AA"/>
                    <cell row="19"  column="3" value="AA"/>
                    <cell row="20"  column="3" value="CC"/>
                    <cell row="21"  column="3" value="CC"/>
                    <cell row="22"  column="3" value="AA"/>
                    <cell row="23"  column="3" value="AA"/>
                    <cell row="24"  column="3" value="AA"/>
                    <cell row="25"  column="3" value="TT"/>
                    <cell row="26"  column="3" value="TT"/>
                    <cell row="27"  column="3" value="AA"/>

                    <cell row="0"   column="4" value="0.95"/>
                    <cell row="1"   column="4" value="0.95"/>
                    <cell row="2"   column="4" value="0.95"/>
                    <cell row="3"   column="4" value="0.95"/>
                    <cell row="4"   column="4" value="0.95"/>
                    <cell row="5"   column="4" value="0.95"/>
                    <cell row="6"   column="4" value="0.95"/>
                    <cell row="7"   column="4" value="0.95"/>
                    <cell row="8"   column="4" value="0.95"/>
                    <cell row="9"   column="4" value="0.95"/>
                    <cell row="10"  column="4" value="0.95"/>
                    <cell row="11"  column="4" value="0.95"/>
                    <cell row="12"  column="4" value="0.95"/>
                    <cell row="13"  column="4" value="0.95"/>
                    <cell row="14"  column="4" value="0.95"/>
                    <cell row="15"  column="4" value="0.95"/>
                    <cell row="16"  column="4" value="0.95"/>
                    <cell row="17"  column="4" value="0.95"/>
                    <cell row="18"  column="4" value="0.95"/>
                    <cell row="19"  column="4" value="0.95"/>
                    <cell row="20"  column="4" value="0.95"/>
                    <cell row="21"  column="4" value="0.95"/>
                    <cell row="22"  column="4" value="0.95"/>
                    <cell row="23"  column="4" value="0.95"/>
                    <cell row="24"  column="4" value="0.95"/>
                    <cell row="25"  column="4" value="0.95"/>
                    <cell row="26"  column="4" value="0.95"/>
                    <cell row="27"  column="4" value="0.95"/>
                </rows>
            </table>
            <table id="detailJianKangGuanLiCuoShi">
                <headers>
                    <header column="0" value="措施icon"/>
                    <header column="1" value="措施"/>
                </headers>
                <rows>
                    <cell row="0"   column="0" value="/Users/zhaolisong/Desktop/projects/cooltoo/parse_pdf/templates/template_medicine_selected/measure_header.jpg"/>
                    <cell row="1"   column="0" value="/Users/zhaolisong/Desktop/projects/cooltoo/parse_pdf/templates/template_medicine_selected/measure_header.jpg"/>
                    <cell row="2"   column="0" value="/Users/zhaolisong/Desktop/projects/cooltoo/parse_pdf/templates/template_medicine_selected/measure_header.jpg"/>
                    <cell row="3"   column="0" value="/Users/zhaolisong/Desktop/projects/cooltoo/parse_pdf/templates/template_medicine_selected/measure_header.jpg"/>
                    <cell row="4"   column="0" value="/Users/zhaolisong/Desktop/projects/cooltoo/parse_pdf/templates/template_medicine_selected/measure_header.jpg"/>
                    <cell row="5"   column="0" value="/Users/zhaolisong/Desktop/projects/cooltoo/parse_pdf/templates/template_medicine_selected/measure_header.jpg"/>
                    <cell row="6"   column="0" value="/Users/zhaolisong/Desktop/projects/cooltoo/parse_pdf/templates/template_medicine_selected/measure_header.jpg"/>
                    <cell row="7"   column="0" value="/Users/zhaolisong/Desktop/projects/cooltoo/parse_pdf/templates/template_medicine_selected/measure_header.jpg"/>
                    <cell row="8"   column="0" value="/Users/zhaolisong/Desktop/projects/cooltoo/parse_pdf/templates/template_medicine_selected/measure_header.jpg"/>

                    <cell row="0"   column="1" value="">
                        <![CDATA[<style font_color="#607b3f" font_size="14" bold="true">减肥：</style> <br/> <br/>
    控制体重，尤其是避免绝经后肥胖]]>
                    </cell>
                    <cell row="1"   column="1" value="">
                        <![CDATA[<style font_color="#607b3f" font_size="14" bold="true">减肥：</style> <br/> <br/>
    控制体重，尤其是避免绝经后肥胖尤其是避免绝经后肥胖尤其是避免绝经后肥胖]]>
                    </cell>
                    <cell row="2"   column="1" value="">
                        <![CDATA[<style font_color="#607b3f" font_size="14" bold="true">减肥：</style> <br/> <br/>
    控制体重，尤其是避免绝经后肥胖尤其是避免绝经后肥胖尤其是避免绝经后肥胖]]>
                    </cell>
                    <cell row="3"   column="1" value="">
                        <![CDATA[<style font_color="#607b3f" font_size="14" bold="true">减肥：</style> <br/> <br/>
    控制体重，尤其是避免绝经后肥胖尤其是避免绝经后肥胖尤其是避免绝经后肥胖]]>
                    </cell>
                    <cell row="4"   column="1" value="">
                        <![CDATA[<style font_color="#607b3f" font_size="14" bold="true">减肥：</style> <br/> <br/>
    控制体重，尤其是避免绝经后肥胖尤其是避免绝经后肥胖尤其是避免绝经后肥胖]]>
                    </cell>
                    <cell row="5"   column="1" value="">
                        <![CDATA[<style font_color="#607b3f" font_size="14" bold="true">减肥：</style> <br/> <br/>
    控制体重，尤其是避免绝经后肥胖尤其是避免绝经后肥胖尤其是避免绝经后肥胖]]>
                    </cell>
                    <cell row="6"   column="1" value="">
                        <![CDATA[<style font_color="#607b3f" font_size="14" bold="true">减肥：</style> <br/> <br/>
    控制体重，尤其是避免绝经后肥胖尤其是避免绝经后肥胖尤其是避免绝经后肥胖]]>
                    </cell>
                    <cell row="7"   column="1" value="">
                        <![CDATA[<style font_color="#607b3f" font_size="14" bold="true">减肥：</style> <br/> <br/>
    控制体重，尤其是避免绝经后肥胖尤其是避免绝经后肥胖尤其是避免绝经后肥胖]]>
                    </cell>
                    <cell row="8"   column="1" value="">
                        <![CDATA[<style font_color="#607b3f" font_size="14" bold="true">减肥：</style> <br/> <br/>
    控制体重，尤其是避免绝经后肥胖尤其是避免绝经后肥胖尤其是避免绝经后肥胖]]>
                    </cell>
                </rows>
            </table>
        </group>








        <group order="3" id="catalog_4_3" value="4 3" catalog="4 3">
            <parameter id="detailJiBing" value="胃癌"/>
            <parameter id="detailJiBingEnglish" value="Mammary Cancer"/>
            <parameter id="detailZhibingjiyinJianChu" value="">
                <![CDATA[基因名词：<style italic="true">MUTYH</style> <br/> 该基因突变的可致疾病：胃癌 家族性腺瘤性息肉病 <br/>]]>
            </parameter>
            <parameter id="detailFengXianJiYinPingFen" value="0.98"/>
            <parameter id="detailFengXianJiYinPingFenMiaoShu" value="与东亚人群相比，您患肺癌的相对风险降低 63.36%，是普通人的 0.37 倍。"/>
            <parameter id="detailRenQunPingJunFaBingLv" value="0.0280%"/>
            <parameter id="detailGeRenFaBingLv" value="0.0103%"/>
            <parameter id="detailJiBingGaiShu" value="">
                <![CDATA[肺癌是发病率和死亡率增长最快，对人群健康和生命威胁最大的恶性肿瘤之一。近年来肺癌的发病率和死亡率均明显增高，男性肺癌发病率和死亡率均占所有恶性肿瘤的第 一位，女性发病率和死亡率占第二位。<br/>
长期大量吸烟与肺癌的发生有非常密切的关系。已长期大量吸烟者患肺癌的概率是不吸烟者的 10 ~ 20 倍，开始吸烟的年龄越小，患肺癌的几 率越高。被动吸烟者肺癌患病率也明显增加。<br/>
城市居民肺癌的发病率比农村高，可能与城市大气污染和烟尘中含有致癌物质有关。<br/><br/>
 <style font="fzltchjw" font_color="#607b3f" font_size="14">危害因素</style><br/>
 <style font_color="#607b3f" font_size="5">______________________________________________________________________________</style><br/><br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">吸烟：</style> <br/>
目前认为吸烟是肺癌的最重要的高危因素。烟草中有超过 3000 种化学物质，其中多链芳香烃类化合物（如：苯并芘）和 亚硝胺均有很强的致癌活性。<br/><br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">职业和环境接触：</style> <br/>
肺癌是职业癌中最重要的一种。估约 10% 的肺癌患者有环境和职业接触史。<br/>
· 现已证明以下9种职业环境致癌物增加肺癌的发生率：铝制品的副产品、砷、石棉、bis-chloromethylether、铬化合物、 焦炭炉、芥子气、含镍的杂质、氯乙烯。<br/> 
· 长期接触铍、镉、硅、福尔马林等物质也会增加肺癌的发病率。<br/> 
· 煤气、沥青、炼焦工人肺癌发病率较一般人群为高。<br/> 
· 空气污染，特别是工业废气均能引发肺癌。<br/> <br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">电离辐射：</style> <br/>
肺脏是对放射线较为敏感的器官。美国曾有报道开采放射性矿石的矿工 70% ~ 80% 死于放射引起的职业性肺癌。日本原子弹爆炸幸存者中患肺癌者显著增加。距爆心距离越近，其死于肺癌者明显增加。<br/><br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">既往肺部慢性感染：</style><br/>
 如肺结核、支气管扩张症等患者，支气管上皮在慢性感染过程中可能化生为鳞状上皮致使癌变，但较为少见。<br/>  <br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">遗传因素：</style> <br/>
· 遗传因素（家族聚集、遗传易感性）可能在对环境致癌物易感的人群和/或个体中起重要作用。<br/> 
 · 免疫功能降低，代谢、内分泌功能失调等也可能在肺癌的发生中起重要作用。<br/><br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">大气污染：</style><br/>
发达国家肺癌的发病率高，主要原因是由于含有苯并芘致癌烃等有害物质污染大气有关。大气污染与吸烟对肺癌的发病率 可能互相促进，起协同作用。<br/><br/>
 <style font="fzltchjw" font_color="#607b3f" font_size="14">高危人群</style> <br/>
 <style font_color="#607b3f" font_size="5">______________________________________________________________________________</style><br/><br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">（a）</style>40 岁以上的长期吸烟者（开始吸烟的年龄愈小，吸烟年数愈多，吸烟量愈大，则危险愈大）<br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">（b）</style>经常接触煤烟或油烟者<br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">（c）</style>有过量放射线照射者 <br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">（d）</style>职业上接触无机砷、石棉、铬、镍等的人 <br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">（e）</style>慢性肺部疾病患者：如慢性支气管炎、肺结核等 <br/><br/>
<style font="fzltchjw" font_color="#607b3f" font_size="14">如何预防</style> <br/>
 <style font_color="#607b3f" font_size="5">______________________________________________________________________________</style><br/><br/>
肺癌是可以预防的。在生活中注意以下方面，做到有效预防。<br/><br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">远离烟草：</style> <br/>
烟民在指导下制定戒烟计划。拒绝二手烟污染，特别要警惕三手烟对婴幼儿和青少年的健康危害! <br/><br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">室内油烟污染：</style> <br/>
包括北方地区取暖和烧饭的燃煤污染、城市居民烹调产生的油烟危害，特别是没有科学正确地使用厨房抽油烟机。 <br/><br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">新居乔迁及装修：</style> <br/>
 修材料和漆料一定要选购绿色合格产品，不要使用含氡量高的建筑和装修材料。在装修结束入住以前，要请当地环保部门验收合格后再入住。 <br/><br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">减少大气污染的暴露，远离水污染：</style> <br/>
大气污染、沉降指数、烟雾指数、苯并芘等暴露剂量与肺癌的发生率成正相关关系。 <br/><br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">避免职业和环境致癌因素：</style> <br/>
 重视职业保护和职业病防治。在主要重工业地区、煤矿和金属矿区、石油和石化地区、核工业基地等地区，每年需进行一次体检或肺癌筛查。 <br/><br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">保持心情愉快：</style> <br/>
特别是那些长期性格内向、性情孤僻和处于郁闷心情状态的中老年人。要善于同人沟通，苦闷烦躁时尤为重要。症状严重时要及时到心理科医生寻求帮助，必要时接受心理治疗和药物治疗。 <br/><br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">有肺癌家族史的人：</style> <br/>
重视健康体检和防癌体检，每年定期体检中需要加做防癌检查项目，如进行胸部 CT 扫描检查等。 <br/><br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">健康的生活方式：</style> <br/>
不吸烟，不酗酒，注意规律饮食和睡眠，加强身体锻炼。 <br/><br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">科学饮食：</style> <br/>
增加饮食中蔬菜、水果等可以预防肺癌。  <br/><br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">重视癌前病变的治疗：</style> <br/>
 既往有肺结核、肺部炎症病史者要定期到专科医院就诊和规范治疗。<br/>]]>
            </parameter>
            <parameter id="detailCanKaoWenXian" value="">
                <![CDATA[1. Bogdanova, N. et al. Association of two mutations in the CHEK2 gene with breast cancer. Int J Cancer 116, 263-6 (2005).
<br/><br/>2. Cai, Q. et al. Genome-wide association study identifies breast cancer risk variant at 10q21.2: results from the Asia Breast Cancer Consortium. Hum Mol Genet 20, 4991-9 (2011).
<br/><br/>3. Cai, Q. et al. Genome-wide association analysis in East Asians identifies breast cancer susceptibility loci at 1q32.1, 5q14.3 and 15q26.1. Nat Genet 46, 886-90 (2014).
<br/><br/>4. Chen, F. et al. A genome-wide association study of breast cancer in women of African ancestry. Hum Genet 132, 39-48 (2013).
<br/><br/>5. Chen, J.J., Silver, D., Cantor, S., Livingston, D.M. &amp; Scully, R. BRCA1, BRCA2, and Rad51 operate in a common DNA damage response pathway. Cancer Res 59, 1752s-1756s (1999).
<br/><br/>6. Easton, D.F. et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447, 1087-93 (2007).
<br/><br/>7. Elgazzar, S. et al. A genome-wide association study identifies a genetic variant in the SIAH2 locus associated with hormonal receptor-positive breast cancer in Japanese. J Hum Genet 57, 766-71 (2012).
<br/><br/>8. Fletcher, O. et al. Novel breast cancer susceptibility locus at 9q31.2: results of a genome-wide association study. J Natl Cancer Inst 103, 425-35 (2011).
<br/><br/>9. Frank, B. et al. BRIP1 (BACH1) variants and familial breast cancer risk: a case-control study. BMC Cancer 7, 83 (2007).
<br/><br/>10. Fukuda, T. et al. Alterations of the double-strand break repair gene MRE11 in cancer. Cancer Res 61, 23-6 (2001).
<br/><br/>11. Garcia-Closas, M. et al. Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet 45, 392-8, 398e1-2 (2013).
<br/><br/>12. Kim, H.C. et al. A genome-wide association study identifies a breast cancer risk variant in ERBB4 at 2q34: results from the Seoul Breast Cancer Study. Breast Cancer Res 14, R56 (2012).
<br/><br/>13. Li, J. et al. A combined analysis of genome-wide association studies in breast cancer. Breast Cancer Res Treat 126, 717-27 (2011).
<br/><br/>14. Long, J. et al. Identification of a functional genetic variant at 16q12.1 for breast cancer risk: results from the Asia Breast Cancer Consortium. PLoS Genet 6, e1001002 (2010).
<br/><br/>15. Long, J. et al. Genome-wide association study in east Asians identifies novel susceptibility loci for breast cancer. PLoS Genet 8, e1002532 (2012).
<br/><br/>16. Lynch, E.D. et al. Inherited mutations in PTEN that are associated with breast cancer, cowden disease, and juvenile polyposis. Am J Hum Genet 61, 1254-60 (1997).
<br/><br/>17. Masciari, S. et al. Germline E-cadherin mutations in familial lobular breast cancer. J Med Genet 44, 726-31 (2007).
<br/><br/>18. Merino, D. &amp; Malkin, D. p53 and hereditary cancer. Subcell Biochem 85, 1-16 (2014).
<br/><br/>19. Michailidou, K. et al. Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet 45, 353-61, 361e1-2 (2013).
<br/><br/>20. Milne, R.L. Variants in the ATM gene and breast cancer susceptibility. Genome Med 1, 12 (2009).
<br/><br/>21. Monsees, G.M., Kraft, P., Chanock, S.J., Hunter, D.J. &amp; Han, J. Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk. Breast Cancer Res Treat 125, 207-14 (2011).
<br/><br/>22. Rebbeck, T.R. et al. Genetic heterogeneity in hereditary breast cancer: role of BRCA1 and BRCA2. Am J Hum Genet 59, 547-53 (1996).
<br/><br/>23. Rennert, G. et al. MutYH mutation carriers have increased breast cancer risk. Cancer 118, 1989-93 (2012). 24. Rinella, E.S. et al. Genetic variants associated with breast cancer risk for Ashkenazi Jewish women with strong family histories but no identifiable BRCA1/2 mutation. Hum Genet 132, 523-36 (2013).
<br/><br/>25. Siddiq, A. et al. A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. Hum Mol Genet 21, 5373-84 (2012).
<br/><br/>26. Song, C. et al. A genome-wide scan for breast cancer risk haplotypes among African American women. PLoS One 8, e57298 (2013).
<br/><br/>27. Stone, J.G. et al. Contribution of germline MLH1 and MSH2 mutations to lobular carcinoma in situ of the breast. Cancer Lett 167, 171-4 (2001).
<br/><br/>28. Thai, T.H. et al. Mutations in the BRCA1-associated RING domain (BARD1) gene in primary breast, ovarian and uterine cancers. Hum Mol Genet 7, 195-202 (1998).
<br/><br/>29. Tischkowitz, M. et al. Rare germline mutations in PALB2 and breast cancer risk: a population-based study. Hum Mutat 33, 674-80 (2012).
<br/><br/>30. Turnbull, C. et al. Genome-wide association study identifies five new breast cancer susceptibility loci. Nat Genet 42, 504-7 (2010).
<br/><br/>31. Walsh, T. &amp; King, M.C. Ten genes for inherited breast cancer. Cancer Cell 11, 103-5 (2007).
<br/><br/>32. Zheng, W. et al. Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1. Nat Genet 41, 324-8 (2009).
]]>
            </parameter>
            <table id="detailZhiBingJiYinTuBian">
                <headers>
                    <header column="0" value="基因"/>
                    <header column="1" value="突变位置"/>
                    <header column="2" value="类型"/>
                    <header column="3" value="致病性证据 *"/>
                    <header column="4" value="人群频率 **"/>
                </headers>
                <rows>
                    <cell row="0" column="0" value="MUTYH"/>
                    <cell row="0" column="1" value="NM_001128425.1:c.934-2A>G"/>
                    <cell row="0" column="2" value="杂合，可变剪切位点突变 splice acceptor variant"/>
                    <cell row="0" column="3" value="Likely pathogenic（2 例）; Probably pathogencic（1 例）"/>
                    <cell row="0" column="4" value="1%"/>
                </rows>
            </table>
            <table id="detailZhiBingJiYinLieBiao">
                <headers>
                    <header column="0" value="基因名称"/>
                    <header column="1" value="检测点位数"/>
                    <header column="2" value="变异点位"/>
                    <header column="3" value="检测结果"/>
                </headers>
                <rows>
                    <cell row="0"  column="0" value="ATM"/>
                    <cell row="1"  column="0" value="BARD1"/>
                    <cell row="2"  column="0" value="BRCA1"/>
                    <cell row="3"  column="0" value="BRCA2"/>
                    <cell row="4"  column="0" value="BRIP1"/>
                    <cell row="5"  column="0" value="CDH1"/>
                    <cell row="6"  column="0" value="CHEK2"/>

                    <cell row="0"  column="1" value="150"/>
                    <cell row="1"  column="1" value="14"/>
                    <cell row="2"  column="1" value="320"/>
                    <cell row="3"  column="1" value="382"/>
                    <cell row="4"  column="1" value="37"/>
                    <cell row="5"  column="1" value="9"/>
                    <cell row="6"  column="1" value="40"/>

                    <cell row="0"  column="2" value="无"/>
                    <cell row="1"  column="2" value="无"/>
                    <cell row="2"  column="2" value="rs77542170"/>
                    <cell row="3"  column="2" value="无"/>
                    <cell row="4"  column="2" value="rs77542170"/>
                    <cell row="5"  column="2" value="无"/>
                    <cell row="6"  column="2" value="无"/>

                    <cell row="0"  column="3" value="（-）"/>
                    <cell row="1"  column="3" value="（-）"/>
                    <cell row="2"  column="3" value="（+）"/>
                    <cell row="3"  column="3" value="（-）"/>
                    <cell row="4"  column="3" value="（+）"/>
                    <cell row="5"  column="3" value="（-）"/>
                    <cell row="6"  column="3" value="（-）"/>
                </rows>
            </table>
            <table id="detailFengXianJiYinLieBiao">
                <headers>
                    <header column="0" value="基因点位"/>
                    <header column="1" value="参考等位基因"/>
                    <header column="2" value="风险等位基因"/>
                    <header column="3" value="个人基因型检出结果"/>
                    <header column="4" value="相对风险值"/>
                </headers>
                <rows>
                    <cell row="0"   column="0" value="rs000000001"/>
                    <cell row="1"   column="0" value="rs000000002"/>
                    <cell row="2"   column="0" value="rs000000003"/>
                    <cell row="3"   column="0" value="rs000000004"/>
                    <cell row="4"   column="0" value="rs000000005"/>
                    <cell row="5"   column="0" value="rs000000006"/>
                    <cell row="6"   column="0" value="rs000000008"/>
                    <cell row="7"   column="0" value="rs000000009"/>
                    <cell row="8"   column="0" value="rs000000010"/>
                    <cell row="9"   column="0" value="rs000000011"/>
                    <cell row="10"  column="0" value="rs000000012"/>
                    <cell row="11"  column="0" value="rs000000013"/>
                    <cell row="12"  column="0" value="rs000000014"/>
                    <cell row="13"  column="0" value="rs000000015"/>
                    <cell row="14"  column="0" value="rs000000016"/>
                    <cell row="15"  column="0" value="rs000000017"/>
                    <cell row="16"  column="0" value="rs000000018"/>
                    <cell row="17"  column="0" value="rs000000019"/>
                    <cell row="18"  column="0" value="rs000000020"/>
                    <cell row="19"  column="0" value="rs000000021"/>
                    <cell row="20"  column="0" value="rs000000022"/>
                    <cell row="21"  column="0" value="rs000000023"/>
                    <cell row="22"  column="0" value="rs000000024"/>
                    <cell row="23"  column="0" value="rs000000025"/>
                    <cell row="24"  column="0" value="rs000000026"/>
                    <cell row="25"  column="0" value="rs000000027"/>
                    <cell row="26"  column="0" value="rs000000028"/>
                    <cell row="27"  column="0" value="rs000000029"/>

                    <cell row="0"   column="1" value="C"/>
                    <cell row="1"   column="1" value="C"/>
                    <cell row="2"   column="1" value="G"/>
                    <cell row="3"   column="1" value="T"/>
                    <cell row="4"   column="1" value="C"/>
                    <cell row="5"   column="1" value="T"/>
                    <cell row="6"   column="1" value="C"/>
                    <cell row="7"   column="1" value="A"/>
                    <cell row="8"   column="1" value="A"/>
                    <cell row="9"   column="1" value="C"/>
                    <cell row="10"  column="1" value="A"/>
                    <cell row="11"  column="1" value="A"/>
                    <cell row="12"  column="1" value="C"/>
                    <cell row="13"  column="1" value="C"/>
                    <cell row="14"  column="1" value="A"/>
                    <cell row="15"  column="1" value="C"/>
                    <cell row="16"  column="1" value="A"/>
                    <cell row="17"  column="1" value="T"/>
                    <cell row="18"  column="1" value="A"/>
                    <cell row="19"  column="1" value="A"/>
                    <cell row="20"  column="1" value="C"/>
                    <cell row="21"  column="1" value="C"/>
                    <cell row="22"  column="1" value="A"/>
                    <cell row="23"  column="1" value="A"/>
                    <cell row="24"  column="1" value="A"/>
                    <cell row="25"  column="1" value="T"/>
                    <cell row="26"  column="1" value="T"/>
                    <cell row="27"  column="1" value="A"/>

                    <cell row="0"   column="2" value="C"/>
                    <cell row="1"   column="2" value="C"/>
                    <cell row="2"   column="2" value="G"/>
                    <cell row="3"   column="2" value="T"/>
                    <cell row="4"   column="2" value="C"/>
                    <cell row="5"   column="2" value="T"/>
                    <cell row="6"   column="2" value="C"/>
                    <cell row="7"   column="2" value="A"/>
                    <cell row="8"   column="2" value="A"/>
                    <cell row="9"   column="2" value="C"/>
                    <cell row="10"  column="2" value="A"/>
                    <cell row="11"  column="2" value="A"/>
                    <cell row="12"  column="2" value="C"/>
                    <cell row="13"  column="2" value="C"/>
                    <cell row="14"  column="2" value="A"/>
                    <cell row="15"  column="2" value="C"/>
                    <cell row="16"  column="2" value="A"/>
                    <cell row="17"  column="2" value="T"/>
                    <cell row="18"  column="2" value="A"/>
                    <cell row="19"  column="2" value="A"/>
                    <cell row="20"  column="2" value="C"/>
                    <cell row="21"  column="2" value="C"/>
                    <cell row="22"  column="2" value="A"/>
                    <cell row="23"  column="2" value="A"/>
                    <cell row="24"  column="2" value="A"/>
                    <cell row="25"  column="2" value="T"/>
                    <cell row="26"  column="2" value="T"/>
                    <cell row="27"  column="2" value="A"/>

                    <cell row="0"   column="2" value="C"/>
                    <cell row="1"   column="2" value="C"/>
                    <cell row="2"   column="2" value="G"/>
                    <cell row="3"   column="2" value="T"/>
                    <cell row="4"   column="2" value="C"/>
                    <cell row="5"   column="2" value="T"/>
                    <cell row="6"   column="2" value="C"/>
                    <cell row="7"   column="2" value="A"/>
                    <cell row="8"   column="2" value="A"/>
                    <cell row="9"   column="2" value="C"/>
                    <cell row="10"  column="2" value="A"/>
                    <cell row="11"  column="2" value="A"/>
                    <cell row="12"  column="2" value="C"/>
                    <cell row="13"  column="2" value="C"/>
                    <cell row="14"  column="2" value="A"/>
                    <cell row="15"  column="2" value="C"/>
                    <cell row="16"  column="2" value="A"/>
                    <cell row="17"  column="2" value="T"/>
                    <cell row="18"  column="2" value="A"/>
                    <cell row="19"  column="2" value="A"/>
                    <cell row="20"  column="2" value="C"/>
                    <cell row="21"  column="2" value="C"/>
                    <cell row="22"  column="2" value="A"/>
                    <cell row="23"  column="2" value="A"/>
                    <cell row="24"  column="2" value="A"/>
                    <cell row="25"  column="2" value="T"/>
                    <cell row="26"  column="2" value="T"/>
                    <cell row="27"  column="2" value="A"/>

                    <cell row="0"   column="3" value="CC"/>
                    <cell row="1"   column="3" value="CC"/>
                    <cell row="2"   column="3" value="GG"/>
                    <cell row="3"   column="3" value="TT"/>
                    <cell row="4"   column="3" value="CC"/>
                    <cell row="5"   column="3" value="TT"/>
                    <cell row="6"   column="3" value="CC"/>
                    <cell row="7"   column="3" value="AA"/>
                    <cell row="8"   column="3" value="AA"/>
                    <cell row="9"   column="3" value="CC"/>
                    <cell row="10"  column="3" value="AA"/>
                    <cell row="11"  column="3" value="AA"/>
                    <cell row="12"  column="3" value="CC"/>
                    <cell row="13"  column="3" value="CC"/>
                    <cell row="14"  column="3" value="AA"/>
                    <cell row="15"  column="3" value="CC"/>
                    <cell row="16"  column="3" value="AA"/>
                    <cell row="17"  column="3" value="TT"/>
                    <cell row="18"  column="3" value="AA"/>
                    <cell row="19"  column="3" value="AA"/>
                    <cell row="20"  column="3" value="CC"/>
                    <cell row="21"  column="3" value="CC"/>
                    <cell row="22"  column="3" value="AA"/>
                    <cell row="23"  column="3" value="AA"/>
                    <cell row="24"  column="3" value="AA"/>
                    <cell row="25"  column="3" value="TT"/>
                    <cell row="26"  column="3" value="TT"/>
                    <cell row="27"  column="3" value="AA"/>

                    <cell row="0"   column="4" value="0.95"/>
                    <cell row="1"   column="4" value="0.95"/>
                    <cell row="2"   column="4" value="0.95"/>
                    <cell row="3"   column="4" value="0.95"/>
                    <cell row="4"   column="4" value="0.95"/>
                    <cell row="5"   column="4" value="0.95"/>
                    <cell row="6"   column="4" value="0.95"/>
                    <cell row="7"   column="4" value="0.95"/>
                    <cell row="8"   column="4" value="0.95"/>
                    <cell row="9"   column="4" value="0.95"/>
                    <cell row="10"  column="4" value="0.95"/>
                    <cell row="11"  column="4" value="0.95"/>
                    <cell row="12"  column="4" value="0.95"/>
                    <cell row="13"  column="4" value="0.95"/>
                    <cell row="14"  column="4" value="0.95"/>
                    <cell row="15"  column="4" value="0.95"/>
                    <cell row="16"  column="4" value="0.95"/>
                    <cell row="17"  column="4" value="0.95"/>
                    <cell row="18"  column="4" value="0.95"/>
                    <cell row="19"  column="4" value="0.95"/>
                    <cell row="20"  column="4" value="0.95"/>
                    <cell row="21"  column="4" value="0.95"/>
                    <cell row="22"  column="4" value="0.95"/>
                    <cell row="23"  column="4" value="0.95"/>
                    <cell row="24"  column="4" value="0.95"/>
                    <cell row="25"  column="4" value="0.95"/>
                    <cell row="26"  column="4" value="0.95"/>
                    <cell row="27"  column="4" value="0.95"/>
                </rows>
            </table>
            <table id="detailJianKangGuanLiCuoShi">
                <headers>
                    <header column="0" value="措施icon"/>
                    <header column="1" value="措施"/>
                </headers>
                <rows>
                    <cell row="0"   column="0" value="/Users/zhaolisong/Desktop/projects/cooltoo/parse_pdf/templates/template_medicine_selected/measure_header.jpg"/>
                    <cell row="1"   column="0" value="/Users/zhaolisong/Desktop/projects/cooltoo/parse_pdf/templates/template_medicine_selected/measure_header.jpg"/>
                    <cell row="2"   column="0" value="/Users/zhaolisong/Desktop/projects/cooltoo/parse_pdf/templates/template_medicine_selected/measure_header.jpg"/>
                    <cell row="3"   column="0" value="/Users/zhaolisong/Desktop/projects/cooltoo/parse_pdf/templates/template_medicine_selected/measure_header.jpg"/>
                    <cell row="4"   column="0" value="/Users/zhaolisong/Desktop/projects/cooltoo/parse_pdf/templates/template_medicine_selected/measure_header.jpg"/>
                    <cell row="5"   column="0" value="/Users/zhaolisong/Desktop/projects/cooltoo/parse_pdf/templates/template_medicine_selected/measure_header.jpg"/>
                    <cell row="6"   column="0" value="/Users/zhaolisong/Desktop/projects/cooltoo/parse_pdf/templates/template_medicine_selected/measure_header.jpg"/>
                    <cell row="7"   column="0" value="/Users/zhaolisong/Desktop/projects/cooltoo/parse_pdf/templates/template_medicine_selected/measure_header.jpg"/>
                    <cell row="8"   column="0" value="/Users/zhaolisong/Desktop/projects/cooltoo/parse_pdf/templates/template_medicine_selected/measure_header.jpg"/>

                    <cell row="0"   column="1" value="">
                        <![CDATA[<style font_color="#607b3f" font_size="14" bold="true">减肥：</style> <br/> <br/>
    控制体重，尤其是避免绝经后肥胖]]>
                    </cell>
                    <cell row="1"   column="1" value="">
                        <![CDATA[<style font_color="#607b3f" font_size="14" bold="true">减肥：</style> <br/> <br/>
    控制体重，尤其是避免绝经后肥胖尤其是避免绝经后肥胖尤其是避免绝经后肥胖]]>
                    </cell>
                    <cell row="2"   column="1" value="">
                        <![CDATA[<style font_color="#607b3f" font_size="14" bold="true">减肥：</style> <br/> <br/>
    控制体重，尤其是避免绝经后肥胖尤其是避免绝经后肥胖尤其是避免绝经后肥胖]]>
                    </cell>
                    <cell row="3"   column="1" value="">
                        <![CDATA[<style font_color="#607b3f" font_size="14" bold="true">减肥：</style> <br/> <br/>
    控制体重，尤其是避免绝经后肥胖尤其是避免绝经后肥胖尤其是避免绝经后肥胖]]>
                    </cell>
                    <cell row="4"   column="1" value="">
                        <![CDATA[<style font_color="#607b3f" font_size="14" bold="true">减肥：</style> <br/> <br/>
    控制体重，尤其是避免绝经后肥胖尤其是避免绝经后肥胖尤其是避免绝经后肥胖]]>
                    </cell>
                    <cell row="5"   column="1" value="">
                        <![CDATA[<style font_color="#607b3f" font_size="14" bold="true">减肥：</style> <br/> <br/>
    控制体重，尤其是避免绝经后肥胖尤其是避免绝经后肥胖尤其是避免绝经后肥胖]]>
                    </cell>
                    <cell row="6"   column="1" value="">
                        <![CDATA[<style font_color="#607b3f" font_size="14" bold="true">减肥：</style> <br/> <br/>
    控制体重，尤其是避免绝经后肥胖尤其是避免绝经后肥胖尤其是避免绝经后肥胖]]>
                    </cell>
                    <cell row="7"   column="1" value="">
                        <![CDATA[<style font_color="#607b3f" font_size="14" bold="true">减肥：</style> <br/> <br/>
    控制体重，尤其是避免绝经后肥胖尤其是避免绝经后肥胖尤其是避免绝经后肥胖]]>
                    </cell>
                    <cell row="8"   column="1" value="">
                        <![CDATA[<style font_color="#607b3f" font_size="14" bold="true">减肥：</style> <br/> <br/>
    控制体重，尤其是避免绝经后肥胖尤其是避免绝经后肥胖尤其是避免绝经后肥胖]]>
                    </cell>
                </rows>
            </table>
        </group>








        <group order="4" id="catalog_4_4" value="4 4" catalog="4 4">
            <parameter id="detailJiBing" value="结直肠癌"/>
            <parameter id="detailJiBingEnglish" value="Mammary Cancer"/>
            <parameter id="detailZhibingjiyinJianChu" value="">
                <![CDATA[基因名词：<style italic="true">MUTYH</style> <br/> 该基因突变的可致疾病：结直肠癌 家族性腺瘤性息肉病 <br/>]]>
            </parameter>
            <parameter id="detailFengXianJiYinPingFen" value="0.98"/>
            <parameter id="detailFengXianJiYinPingFenMiaoShu" value="与东亚人群相比，您患肺癌的相对风险降低 63.36%，是普通人的 0.37 倍。"/>
            <parameter id="detailRenQunPingJunFaBingLv" value="0.0280%"/>
            <parameter id="detailGeRenFaBingLv" value="0.0103%"/>
            <parameter id="detailJiBingGaiShu" value="">
                <![CDATA[肺癌是发病率和死亡率增长最快，对人群健康和生命威胁最大的恶性肿瘤之一。近年来肺癌的发病率和死亡率均明显增高，男性肺癌发病率和死亡率均占所有恶性肿瘤的第 一位，女性发病率和死亡率占第二位。<br/>
长期大量吸烟与肺癌的发生有非常密切的关系。已长期大量吸烟者患肺癌的概率是不吸烟者的 10 ~ 20 倍，开始吸烟的年龄越小，患肺癌的几 率越高。被动吸烟者肺癌患病率也明显增加。<br/>
城市居民肺癌的发病率比农村高，可能与城市大气污染和烟尘中含有致癌物质有关。<br/><br/>
 <style font="fzltchjw" font_color="#607b3f" font_size="14">危害因素</style><br/>
 <style font_color="#607b3f" font_size="5">______________________________________________________________________________</style><br/><br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">吸烟：</style> <br/>
目前认为吸烟是肺癌的最重要的高危因素。烟草中有超过 3000 种化学物质，其中多链芳香烃类化合物（如：苯并芘）和 亚硝胺均有很强的致癌活性。<br/><br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">职业和环境接触：</style> <br/>
肺癌是职业癌中最重要的一种。估约 10% 的肺癌患者有环境和职业接触史。<br/>
· 现已证明以下9种职业环境致癌物增加肺癌的发生率：铝制品的副产品、砷、石棉、bis-chloromethylether、铬化合物、 焦炭炉、芥子气、含镍的杂质、氯乙烯。<br/> 
· 长期接触铍、镉、硅、福尔马林等物质也会增加肺癌的发病率。<br/> 
· 煤气、沥青、炼焦工人肺癌发病率较一般人群为高。<br/> 
· 空气污染，特别是工业废气均能引发肺癌。<br/> <br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">电离辐射：</style> <br/>
肺脏是对放射线较为敏感的器官。美国曾有报道开采放射性矿石的矿工 70% ~ 80% 死于放射引起的职业性肺癌。日本原子弹爆炸幸存者中患肺癌者显著增加。距爆心距离越近，其死于肺癌者明显增加。<br/><br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">既往肺部慢性感染：</style><br/>
 如肺结核、支气管扩张症等患者，支气管上皮在慢性感染过程中可能化生为鳞状上皮致使癌变，但较为少见。<br/>  <br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">遗传因素：</style> <br/>
· 遗传因素（家族聚集、遗传易感性）可能在对环境致癌物易感的人群和/或个体中起重要作用。<br/> 
 · 免疫功能降低，代谢、内分泌功能失调等也可能在肺癌的发生中起重要作用。<br/><br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">大气污染：</style><br/>
发达国家肺癌的发病率高，主要原因是由于含有苯并芘致癌烃等有害物质污染大气有关。大气污染与吸烟对肺癌的发病率 可能互相促进，起协同作用。<br/><br/>
 <style font="fzltchjw" font_color="#607b3f" font_size="14">高危人群</style> <br/>
 <style font_color="#607b3f" font_size="5">______________________________________________________________________________</style><br/><br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">（a）</style>40 岁以上的长期吸烟者（开始吸烟的年龄愈小，吸烟年数愈多，吸烟量愈大，则危险愈大）<br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">（b）</style>经常接触煤烟或油烟者<br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">（c）</style>有过量放射线照射者 <br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">（d）</style>职业上接触无机砷、石棉、铬、镍等的人 <br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">（e）</style>慢性肺部疾病患者：如慢性支气管炎、肺结核等 <br/><br/>
<style font="fzltchjw" font_color="#607b3f" font_size="14">如何预防</style> <br/>
 <style font_color="#607b3f" font_size="5">______________________________________________________________________________</style><br/><br/>
肺癌是可以预防的。在生活中注意以下方面，做到有效预防。<br/><br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">远离烟草：</style> <br/>
烟民在指导下制定戒烟计划。拒绝二手烟污染，特别要警惕三手烟对婴幼儿和青少年的健康危害! <br/><br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">室内油烟污染：</style> <br/>
包括北方地区取暖和烧饭的燃煤污染、城市居民烹调产生的油烟危害，特别是没有科学正确地使用厨房抽油烟机。 <br/><br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">新居乔迁及装修：</style> <br/>
 修材料和漆料一定要选购绿色合格产品，不要使用含氡量高的建筑和装修材料。在装修结束入住以前，要请当地环保部门验收合格后再入住。 <br/><br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">减少大气污染的暴露，远离水污染：</style> <br/>
大气污染、沉降指数、烟雾指数、苯并芘等暴露剂量与肺癌的发生率成正相关关系。 <br/><br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">避免职业和环境致癌因素：</style> <br/>
 重视职业保护和职业病防治。在主要重工业地区、煤矿和金属矿区、石油和石化地区、核工业基地等地区，每年需进行一次体检或肺癌筛查。 <br/><br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">保持心情愉快：</style> <br/>
特别是那些长期性格内向、性情孤僻和处于郁闷心情状态的中老年人。要善于同人沟通，苦闷烦躁时尤为重要。症状严重时要及时到心理科医生寻求帮助，必要时接受心理治疗和药物治疗。 <br/><br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">有肺癌家族史的人：</style> <br/>
重视健康体检和防癌体检，每年定期体检中需要加做防癌检查项目，如进行胸部 CT 扫描检查等。 <br/><br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">健康的生活方式：</style> <br/>
不吸烟，不酗酒，注意规律饮食和睡眠，加强身体锻炼。 <br/><br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">科学饮食：</style> <br/>
增加饮食中蔬菜、水果等可以预防肺癌。  <br/><br/>
 <style font_color="#607b3f" font_size="12" bold="true" line_leading="4">重视癌前病变的治疗：</style> <br/>
 既往有肺结核、肺部炎症病史者要定期到专科医院就诊和规范治疗。<br/>]]>
            </parameter>
            <parameter id="detailCanKaoWenXian" value="">
                <![CDATA[1. Bogdanova, N. et al. Association of two mutations in the CHEK2 gene with breast cancer. Int J Cancer 116, 263-6 (2005).
<br/><br/>2. Cai, Q. et al. Genome-wide association study identifies breast cancer risk variant at 10q21.2: results from the Asia Breast Cancer Consortium. Hum Mol Genet 20, 4991-9 (2011).
<br/><br/>3. Cai, Q. et al. Genome-wide association analysis in East Asians identifies breast cancer susceptibility loci at 1q32.1, 5q14.3 and 15q26.1. Nat Genet 46, 886-90 (2014).
<br/><br/>4. Chen, F. et al. A genome-wide association study of breast cancer in women of African ancestry. Hum Genet 132, 39-48 (2013).
<br/><br/>5. Chen, J.J., Silver, D., Cantor, S., Livingston, D.M. &amp; Scully, R. BRCA1, BRCA2, and Rad51 operate in a common DNA damage response pathway. Cancer Res 59, 1752s-1756s (1999).
<br/><br/>6. Easton, D.F. et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447, 1087-93 (2007).
<br/><br/>7. Elgazzar, S. et al. A genome-wide association study identifies a genetic variant in the SIAH2 locus associated with hormonal receptor-positive breast cancer in Japanese. J Hum Genet 57, 766-71 (2012).
<br/><br/>8. Fletcher, O. et al. Novel breast cancer susceptibility locus at 9q31.2: results of a genome-wide association study. J Natl Cancer Inst 103, 425-35 (2011).
<br/><br/>9. Frank, B. et al. BRIP1 (BACH1) variants and familial breast cancer risk: a case-control study. BMC Cancer 7, 83 (2007).
<br/><br/>10. Fukuda, T. et al. Alterations of the double-strand break repair gene MRE11 in cancer. Cancer Res 61, 23-6 (2001).
<br/><br/>11. Garcia-Closas, M. et al. Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet 45, 392-8, 398e1-2 (2013).
<br/><br/>12. Kim, H.C. et al. A genome-wide association study identifies a breast cancer risk variant in ERBB4 at 2q34: results from the Seoul Breast Cancer Study. Breast Cancer Res 14, R56 (2012).
<br/><br/>13. Li, J. et al. A combined analysis of genome-wide association studies in breast cancer. Breast Cancer Res Treat 126, 717-27 (2011).
<br/><br/>14. Long, J. et al. Identification of a functional genetic variant at 16q12.1 for breast cancer risk: results from the Asia Breast Cancer Consortium. PLoS Genet 6, e1001002 (2010).
<br/><br/>15. Long, J. et al. Genome-wide association study in east Asians identifies novel susceptibility loci for breast cancer. PLoS Genet 8, e1002532 (2012).
<br/><br/>16. Lynch, E.D. et al. Inherited mutations in PTEN that are associated with breast cancer, cowden disease, and juvenile polyposis. Am J Hum Genet 61, 1254-60 (1997).
<br/><br/>17. Masciari, S. et al. Germline E-cadherin mutations in familial lobular breast cancer. J Med Genet 44, 726-31 (2007).
<br/><br/>18. Merino, D. &amp; Malkin, D. p53 and hereditary cancer. Subcell Biochem 85, 1-16 (2014).
<br/><br/>19. Michailidou, K. et al. Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet 45, 353-61, 361e1-2 (2013).
<br/><br/>20. Milne, R.L. Variants in the ATM gene and breast cancer susceptibility. Genome Med 1, 12 (2009).
<br/><br/>21. Monsees, G.M., Kraft, P., Chanock, S.J., Hunter, D.J. &amp; Han, J. Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk. Breast Cancer Res Treat 125, 207-14 (2011).
<br/><br/>22. Rebbeck, T.R. et al. Genetic heterogeneity in hereditary breast cancer: role of BRCA1 and BRCA2. Am J Hum Genet 59, 547-53 (1996).
<br/><br/>23. Rennert, G. et al. MutYH mutation carriers have increased breast cancer risk. Cancer 118, 1989-93 (2012). 24. Rinella, E.S. et al. Genetic variants associated with breast cancer risk for Ashkenazi Jewish women with strong family histories but no identifiable BRCA1/2 mutation. Hum Genet 132, 523-36 (2013).
<br/><br/>25. Siddiq, A. et al. A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. Hum Mol Genet 21, 5373-84 (2012).
<br/><br/>26. Song, C. et al. A genome-wide scan for breast cancer risk haplotypes among African American women. PLoS One 8, e57298 (2013).
<br/><br/>27. Stone, J.G. et al. Contribution of germline MLH1 and MSH2 mutations to lobular carcinoma in situ of the breast. Cancer Lett 167, 171-4 (2001).
<br/><br/>28. Thai, T.H. et al. Mutations in the BRCA1-associated RING domain (BARD1) gene in primary breast, ovarian and uterine cancers. Hum Mol Genet 7, 195-202 (1998).
<br/><br/>29. Tischkowitz, M. et al. Rare germline mutations in PALB2 and breast cancer risk: a population-based study. Hum Mutat 33, 674-80 (2012).
<br/><br/>30. Turnbull, C. et al. Genome-wide association study identifies five new breast cancer susceptibility loci. Nat Genet 42, 504-7 (2010).
<br/><br/>31. Walsh, T. &amp; King, M.C. Ten genes for inherited breast cancer. Cancer Cell 11, 103-5 (2007).
<br/><br/>32. Zheng, W. et al. Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1. Nat Genet 41, 324-8 (2009).
]]>
            </parameter>
            <table id="detailZhiBingJiYinTuBian">
                <headers>
                    <header column="0" value="基因"/>
                    <header column="1" value="突变位置"/>
                    <header column="2" value="类型"/>
                    <header column="3" value="致病性证据 *"/>
                    <header column="4" value="人群频率 **"/>
                </headers>
                <rows>
                    <cell row="0" column="0" value="MUTYH"/>
                    <cell row="0" column="1" value="NM_001128425.1:c.934-2A>G"/>
                    <cell row="0" column="2" value="杂合，可变剪切位点突变 splice acceptor variant"/>
                    <cell row="0" column="3" value="Likely pathogenic（2 例）; Probably pathogencic（1 例）"/>
                    <cell row="0" column="4" value="1%"/>
                </rows>
            </table>
            <table id="detailZhiBingJiYinLieBiao">
                <headers>
                    <header column="0" value="基因名称"/>
                    <header column="1" value="检测点位数"/>
                    <header column="2" value="变异点位"/>
                    <header column="3" value="检测结果"/>
                </headers>
                <rows>
                    <cell row="0"  column="0" value="ATM"/>
                    <cell row="1"  column="0" value="BARD1"/>
                    <cell row="2"  column="0" value="BRCA1"/>
                    <cell row="3"  column="0" value="BRCA2"/>
                    <cell row="4"  column="0" value="BRIP1"/>
                    <cell row="5"  column="0" value="CDH1"/>
                    <cell row="6"  column="0" value="CHEK2"/>

                    <cell row="0"  column="1" value="150"/>
                    <cell row="1"  column="1" value="14"/>
                    <cell row="2"  column="1" value="320"/>
                    <cell row="3"  column="1" value="382"/>
                    <cell row="4"  column="1" value="37"/>
                    <cell row="5"  column="1" value="9"/>
                    <cell row="6"  column="1" value="40"/>

                    <cell row="0"  column="2" value="无"/>
                    <cell row="1"  column="2" value="无"/>
                    <cell row="2"  column="2" value="rs77542170"/>
                    <cell row="3"  column="2" value="无"/>
                    <cell row="4"  column="2" value="rs77542170"/>
                    <cell row="5"  column="2" value="无"/>
                    <cell row="6"  column="2" value="无"/>

                    <cell row="0"  column="3" value="（-）"/>
                    <cell row="1"  column="3" value="（-）"/>
                    <cell row="2"  column="3" value="（+）"/>
                    <cell row="3"  column="3" value="（-）"/>
                    <cell row="4"  column="3" value="（+）"/>
                    <cell row="5"  column="3" value="（-）"/>
                    <cell row="6"  column="3" value="（-）"/>
                </rows>
            </table>
            <table id="detailFengXianJiYinLieBiao">
                <headers>
                    <header column="0" value="基因点位"/>
                    <header column="1" value="参考等位基因"/>
                    <header column="2" value="风险等位基因"/>
                    <header column="3" value="个人基因型检出结果"/>
                    <header column="4" value="相对风险值"/>
                </headers>
                <rows>
                    <cell row="0"   column="0" value="rs000000001"/>
                    <cell row="1"   column="0" value="rs000000002"/>
                    <cell row="2"   column="0" value="rs000000003"/>
                    <cell row="3"   column="0" value="rs000000004"/>
                    <cell row="4"   column="0" value="rs000000005"/>
                    <cell row="5"   column="0" value="rs000000006"/>
                    <cell row="6"   column="0" value="rs000000008"/>
                    <cell row="7"   column="0" value="rs000000009"/>
                    <cell row="8"   column="0" value="rs000000010"/>
                    <cell row="9"   column="0" value="rs000000011"/>
                    <cell row="10"  column="0" value="rs000000012"/>
                    <cell row="11"  column="0" value="rs000000013"/>
                    <cell row="12"  column="0" value="rs000000014"/>
                    <cell row="13"  column="0" value="rs000000015"/>
                    <cell row="14"  column="0" value="rs000000016"/>
                    <cell row="15"  column="0" value="rs000000017"/>
                    <cell row="16"  column="0" value="rs000000018"/>
                    <cell row="17"  column="0" value="rs000000019"/>
                    <cell row="18"  column="0" value="rs000000020"/>
                    <cell row="19"  column="0" value="rs000000021"/>
                    <cell row="20"  column="0" value="rs000000022"/>
                    <cell row="21"  column="0" value="rs000000023"/>
                    <cell row="22"  column="0" value="rs000000024"/>
                    <cell row="23"  column="0" value="rs000000025"/>
                    <cell row="24"  column="0" value="rs000000026"/>
                    <cell row="25"  column="0" value="rs000000027"/>
                    <cell row="26"  column="0" value="rs000000028"/>
                    <cell row="27"  column="0" value="rs000000029"/>

                    <cell row="0"   column="1" value="C"/>
                    <cell row="1"   column="1" value="C"/>
                    <cell row="2"   column="1" value="G"/>
                    <cell row="3"   column="1" value="T"/>
                    <cell row="4"   column="1" value="C"/>
                    <cell row="5"   column="1" value="T"/>
                    <cell row="6"   column="1" value="C"/>
                    <cell row="7"   column="1" value="A"/>
                    <cell row="8"   column="1" value="A"/>
                    <cell row="9"   column="1" value="C"/>
                    <cell row="10"  column="1" value="A"/>
                    <cell row="11"  column="1" value="A"/>
                    <cell row="12"  column="1" value="C"/>
                    <cell row="13"  column="1" value="C"/>
                    <cell row="14"  column="1" value="A"/>
                    <cell row="15"  column="1" value="C"/>
                    <cell row="16"  column="1" value="A"/>
                    <cell row="17"  column="1" value="T"/>
                    <cell row="18"  column="1" value="A"/>
                    <cell row="19"  column="1" value="A"/>
                    <cell row="20"  column="1" value="C"/>
                    <cell row="21"  column="1" value="C"/>
                    <cell row="22"  column="1" value="A"/>
                    <cell row="23"  column="1" value="A"/>
                    <cell row="24"  column="1" value="A"/>
                    <cell row="25"  column="1" value="T"/>
                    <cell row="26"  column="1" value="T"/>
                    <cell row="27"  column="1" value="A"/>

                    <cell row="0"   column="2" value="C"/>
                    <cell row="1"   column="2" value="C"/>
                    <cell row="2"   column="2" value="G"/>
                    <cell row="3"   column="2" value="T"/>
                    <cell row="4"   column="2" value="C"/>
                    <cell row="5"   column="2" value="T"/>
                    <cell row="6"   column="2" value="C"/>
                    <cell row="7"   column="2" value="A"/>
                    <cell row="8"   column="2" value="A"/>
                    <cell row="9"   column="2" value="C"/>
                    <cell row="10"  column="2" value="A"/>
                    <cell row="11"  column="2" value="A"/>
                    <cell row="12"  column="2" value="C"/>
                    <cell row="13"  column="2" value="C"/>
                    <cell row="14"  column="2" value="A"/>
                    <cell row="15"  column="2" value="C"/>
                    <cell row="16"  column="2" value="A"/>
                    <cell row="17"  column="2" value="T"/>
                    <cell row="18"  column="2" value="A"/>
                    <cell row="19"  column="2" value="A"/>
                    <cell row="20"  column="2" value="C"/>
                    <cell row="21"  column="2" value="C"/>
                    <cell row="22"  column="2" value="A"/>
                    <cell row="23"  column="2" value="A"/>
                    <cell row="24"  column="2" value="A"/>
                    <cell row="25"  column="2" value="T"/>
                    <cell row="26"  column="2" value="T"/>
                    <cell row="27"  column="2" value="A"/>

                    <cell row="0"   column="2" value="C"/>
                    <cell row="1"   column="2" value="C"/>
                    <cell row="2"   column="2" value="G"/>
                    <cell row="3"   column="2" value="T"/>
                    <cell row="4"   column="2" value="C"/>
                    <cell row="5"   column="2" value="T"/>
                    <cell row="6"   column="2" value="C"/>
                    <cell row="7"   column="2" value="A"/>
                    <cell row="8"   column="2" value="A"/>
                    <cell row="9"   column="2" value="C"/>
                    <cell row="10"  column="2" value="A"/>
                    <cell row="11"  column="2" value="A"/>
                    <cell row="12"  column="2" value="C"/>
                    <cell row="13"  column="2" value="C"/>
                    <cell row="14"  column="2" value="A"/>
                    <cell row="15"  column="2" value="C"/>
                    <cell row="16"  column="2" value="A"/>
                    <cell row="17"  column="2" value="T"/>
                    <cell row="18"  column="2" value="A"/>
                    <cell row="19"  column="2" value="A"/>
                    <cell row="20"  column="2" value="C"/>
                    <cell row="21"  column="2" value="C"/>
                    <cell row="22"  column="2" value="A"/>
                    <cell row="23"  column="2" value="A"/>
                    <cell row="24"  column="2" value="A"/>
                    <cell row="25"  column="2" value="T"/>
                    <cell row="26"  column="2" value="T"/>
                    <cell row="27"  column="2" value="A"/>

                    <cell row="0"   column="3" value="CC"/>
                    <cell row="1"   column="3" value="CC"/>
                    <cell row="2"   column="3" value="GG"/>
                    <cell row="3"   column="3" value="TT"/>
                    <cell row="4"   column="3" value="CC"/>
                    <cell row="5"   column="3" value="TT"/>
                    <cell row="6"   column="3" value="CC"/>
                    <cell row="7"   column="3" value="AA"/>
                    <cell row="8"   column="3" value="AA"/>
                    <cell row="9"   column="3" value="CC"/>
                    <cell row="10"  column="3" value="AA"/>
                    <cell row="11"  column="3" value="AA"/>
                    <cell row="12"  column="3" value="CC"/>
                    <cell row="13"  column="3" value="CC"/>
                    <cell row="14"  column="3" value="AA"/>
                    <cell row="15"  column="3" value="CC"/>
                    <cell row="16"  column="3" value="AA"/>
                    <cell row="17"  column="3" value="TT"/>
                    <cell row="18"  column="3" value="AA"/>
                    <cell row="19"  column="3" value="AA"/>
                    <cell row="20"  column="3" value="CC"/>
                    <cell row="21"  column="3" value="CC"/>
                    <cell row="22"  column="3" value="AA"/>
                    <cell row="23"  column="3" value="AA"/>
                    <cell row="24"  column="3" value="AA"/>
                    <cell row="25"  column="3" value="TT"/>
                    <cell row="26"  column="3" value="TT"/>
                    <cell row="27"  column="3" value="AA"/>

                    <cell row="0"   column="4" value="0.95"/>
                    <cell row="1"   column="4" value="0.95"/>
                    <cell row="2"   column="4" value="0.95"/>
                    <cell row="3"   column="4" value="0.95"/>
                    <cell row="4"   column="4" value="0.95"/>
                    <cell row="5"   column="4" value="0.95"/>
                    <cell row="6"   column="4" value="0.95"/>
                    <cell row="7"   column="4" value="0.95"/>
                    <cell row="8"   column="4" value="0.95"/>
                    <cell row="9"   column="4" value="0.95"/>
                    <cell row="10"  column="4" value="0.95"/>
                    <cell row="11"  column="4" value="0.95"/>
                    <cell row="12"  column="4" value="0.95"/>
                    <cell row="13"  column="4" value="0.95"/>
                    <cell row="14"  column="4" value="0.95"/>
                    <cell row="15"  column="4" value="0.95"/>
                    <cell row="16"  column="4" value="0.95"/>
                    <cell row="17"  column="4" value="0.95"/>
                    <cell row="18"  column="4" value="0.95"/>
                    <cell row="19"  column="4" value="0.95"/>
                    <cell row="20"  column="4" value="0.95"/>
                    <cell row="21"  column="4" value="0.95"/>
                    <cell row="22"  column="4" value="0.95"/>
                    <cell row="23"  column="4" value="0.95"/>
                    <cell row="24"  column="4" value="0.95"/>
                    <cell row="25"  column="4" value="0.95"/>
                    <cell row="26"  column="4" value="0.95"/>
                    <cell row="27"  column="4" value="0.95"/>
                </rows>
            </table>
            <table id="detailJianKangGuanLiCuoShi">
                <headers>
                    <header column="0" value="措施icon"/>
                    <header column="1" value="措施"/>
                </headers>
                <rows>
                    <cell row="0"   column="0" value="/Users/zhaolisong/Desktop/projects/cooltoo/parse_pdf/templates/template_medicine_selected/measure_header.jpg"/>
                    <cell row="1"   column="0" value="/Users/zhaolisong/Desktop/projects/cooltoo/parse_pdf/templates/template_medicine_selected/measure_header.jpg"/>
                    <cell row="2"   column="0" value="/Users/zhaolisong/Desktop/projects/cooltoo/parse_pdf/templates/template_medicine_selected/measure_header.jpg"/>
                    <cell row="3"   column="0" value="/Users/zhaolisong/Desktop/projects/cooltoo/parse_pdf/templates/template_medicine_selected/measure_header.jpg"/>
                    <cell row="4"   column="0" value="/Users/zhaolisong/Desktop/projects/cooltoo/parse_pdf/templates/template_medicine_selected/measure_header.jpg"/>
                    <cell row="5"   column="0" value="/Users/zhaolisong/Desktop/projects/cooltoo/parse_pdf/templates/template_medicine_selected/measure_header.jpg"/>
                    <cell row="6"   column="0" value="/Users/zhaolisong/Desktop/projects/cooltoo/parse_pdf/templates/template_medicine_selected/measure_header.jpg"/>
                    <cell row="7"   column="0" value="/Users/zhaolisong/Desktop/projects/cooltoo/parse_pdf/templates/template_medicine_selected/measure_header.jpg"/>
                    <cell row="8"   column="0" value="/Users/zhaolisong/Desktop/projects/cooltoo/parse_pdf/templates/template_medicine_selected/measure_header.jpg"/>

                    <cell row="0"   column="1" value="">
                        <![CDATA[<style font_color="#607b3f" font_size="14" bold="true">减肥：</style> <br/> <br/>
    控制体重，尤其是避免绝经后肥胖]]>
                    </cell>
                    <cell row="1"   column="1" value="">
                        <![CDATA[<style font_color="#607b3f" font_size="14" bold="true">减肥：</style> <br/> <br/>
    控制体重，尤其是避免绝经后肥胖尤其是避免绝经后肥胖尤其是避免绝经后肥胖]]>
                    </cell>
                    <cell row="2"   column="1" value="">
                        <![CDATA[<style font_color="#607b3f" font_size="14" bold="true">减肥：</style> <br/> <br/>
    控制体重，尤其是避免绝经后肥胖尤其是避免绝经后肥胖尤其是避免绝经后肥胖]]>
                    </cell>
                    <cell row="3"   column="1" value="">
                        <![CDATA[<style font_color="#607b3f" font_size="14" bold="true">减肥：</style> <br/> <br/>
    控制体重，尤其是避免绝经后肥胖尤其是避免绝经后肥胖尤其是避免绝经后肥胖]]>
                    </cell>
                    <cell row="4"   column="1" value="">
                        <![CDATA[<style font_color="#607b3f" font_size="14" bold="true">减肥：</style> <br/> <br/>
    控制体重，尤其是避免绝经后肥胖尤其是避免绝经后肥胖尤其是避免绝经后肥胖]]>
                    </cell>
                    <cell row="5"   column="1" value="">
                        <![CDATA[<style font_color="#607b3f" font_size="14" bold="true">减肥：</style> <br/> <br/>
    控制体重，尤其是避免绝经后肥胖尤其是避免绝经后肥胖尤其是避免绝经后肥胖]]>
                    </cell>
                    <cell row="6"   column="1" value="">
                        <![CDATA[<style font_color="#607b3f" font_size="14" bold="true">减肥：</style> <br/> <br/>
    控制体重，尤其是避免绝经后肥胖尤其是避免绝经后肥胖尤其是避免绝经后肥胖]]>
                    </cell>
                    <cell row="7"   column="1" value="">
                        <![CDATA[<style font_color="#607b3f" font_size="14" bold="true">减肥：</style> <br/> <br/>
    控制体重，尤其是避免绝经后肥胖尤其是避免绝经后肥胖尤其是避免绝经后肥胖]]>
                    </cell>
                    <cell row="8"   column="1" value="">
                        <![CDATA[<style font_color="#607b3f" font_size="14" bold="true">减肥：</style> <br/> <br/>
    控制体重，尤其是避免绝经后肥胖尤其是避免绝经后肥胖尤其是避免绝经后肥胖]]>
                    </cell>
                </rows>
            </table>
        </group>
    </data>
</pdf>